# 2025年12月21日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 用于无创诊断膀胱尿路上皮癌的尿液新型DNA甲基化生物标志物

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41420251)
**期刊：** Clinical epigenetics
**PMID：** 41420251
**DOI：** 10.1186/s13148-025-01964-3

### 第一部分 原文与翻译

**英文原标题：** Novel DNA methylation biomarkers in urine for non-invasive diagnosis of bladder urothelial carcinoma.

> **英文摘要：**
> Bladder urothelial carcinoma (BLCA) is a common malignant tumor with high invasiveness and recurrence rates, underscoring the need for early diagnosis and effective monitoring. Current diagnostic methods, such as invasive cystoscopy and low-sensitivity urine cytology, have limitations. Oncogene hypermethylation plays a key role in tumorigenesis and progression. However, DNA methylation in BLCA remain underexplored. Identifying and validating new DNA methylation markers in urine samples is crucial to enhance early detection accuracy. In this study, we identified three novel BLCA DNA methylation biomarkers (HIST1H3J, NKX2-4, and YBX3P1 genes), and compared with six known markers (ONECUT2, OTX1, POU4F2, SOX1, TWIST1, VIM). Real-time quantitative methylation-specific PCR (qMSP) was used to detect the methylation levels of biomarkers in 319 urine samples from patients with suspected BLCA. The individual biomarkers of HIST1H3J, NKX2-4, and YBX3P1 achieved Areas Under the Curve (AUCs) of 0.892, 0.914 and 0.871, with accuracies of 84.80%, 85.38% and 81.29%, respectively. In comparison, the six known markers exhibited AUCs ranging from 0.850 to 0.939 and the accuracies of 81.87%-88.30%. These methylation markers can not only identify high-grade BLCA but also low-grade BLCA, highlighting their potential clinical utility. Notably, a four-gene panel (ONECUT2, SOX1, TWIST1 and NKX2-4) significantly improved the detection performance, with an AUC of 0.971 and an accuracy of 92.39%. Our results provide three new DNA methylation markers for BLCA and propose a urine-based DNA methylation detection panel for non-invasive clinical diagnosis.

> **中文摘要：**
> 膀胱尿路上皮癌（BLCA）是一种常见的恶性肿瘤，具有高度侵袭性和高复发率，这凸显了早期诊断和有效监测的必要性。目前的诊断方法（如侵入性膀胱镜检查和低灵敏度的尿液细胞学检查）均存在局限。癌基因的高甲基化在肿瘤发生和进展中起关键作用。然而，BLCA中的DNA甲基化研究仍然不足。识别并验证尿液样本中的新型DNA甲基化标志物对于提高早期检测的准确性至关重要。本研究鉴定了三种新的BLCA DNA甲基化生物标志物（HIST1H3J、NKX2-4和YBX3P1基因），并与六种已知标志物（ONECUT2、OTX1、POU4F2、SOX1、TWIST1、VIM）进行了比较。采用实时定量甲基化特异性PCR（qMSP）检测来自319例疑似BLCA患者尿液样本中这些标志物的甲基化水平。单个标志物HIST1H3J、NKX2-4和YBX3P1的曲线下面积（AUC）分别为0.892、0.914和0.871，准确率分别为84.80%、85.38%和81.29%。相比之下，六种已知标志物的AUC范围为0.850至0.939，准确率为81.87%至88.30%。这些甲基化标志物不仅能够识别高级别BLCA，还能检测低级别BLCA，显示出其潜在的临床应用价值。值得注意的是，一个由四个基因（ONECUT2、SOX1、TWIST1和NKX2-4）组成的联合面板显著提高了检测性能，其AUC为0.971，准确率为92.39%。我们的研究结果提供了三种新的BLCA DNA甲基化标志物，并提出了一种基于尿液的DNA甲基化检测面板，用于无创的临床诊断。

### 第二部分 AI 大师评价

该研究旨在通过筛选和验证尿液样本中的DNA甲基化标志物，实现对膀胱尿路上皮癌的无创早期诊断。研究采用qMSP方法鉴定出三种新基因并与六种已知标志物进行比较，结果显示新标志物具有良好的诊断效能。进一步构建的四基因联合检测模型显著提高了诊断准确性。该研究的创新性在于提出了新的尿液甲基化生物标志物及其高效联合检测方案，为膀胱癌的无创临床筛查提供了有前景的分子工具，但仍需在更大样本和多中心人群中验证其普适性。

---

## 2. Sitravatinib联合Tislelizumab治疗局部复发或转移性三阴性乳腺癌的多队列、单臂、II期临床试验（SPARK试验）

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41420248)
**期刊：** Molecular cancer
**PMID：** 41420248
**DOI：** 10.1186/s12943-025-02505-5

### 第一部分 原文与翻译

**英文原标题：** Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial).

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究报道了Sitravatinib（多靶点酪氨酸激酶抑制剂）与Tislelizumab（抗PD-1单克隆抗体）联合治疗局部复发或转移性三阴性乳腺癌的II期单臂临床试验。多队列设计可能用于探索不同患者亚群的疗效与安全性。此类研究旨在为难治型乳腺癌提供新的免疫联合治疗策略，突显了代谢通路与免疫微环境的双重靶向理念。尽管结果尚未公布，但该试验的设计具有一定创新性，并可能为未来精准免疫治疗探索奠定基础。

---

## 3. 基于参考引导的计算框架利用泛癌单细胞数据集识别微环境代谢亚型与靶点

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41420243)
**期刊：** Genome medicine
**PMID：** 41420243
**DOI：** 10.1186/s13073-025-01572-z

### 第一部分 原文与翻译

**英文原标题：** Reference-guided computational framework identifies microenvironment metabolic subtypes and targets using pan-cancer single-cell datasets.

> **英文摘要：**
> BACKGROUND: Metabolic reprogramming is a hallmark of cancer; however, the mechanisms driving metabolic heterogeneity across diverse cell types in the tumor microenvironment remain poorly understood. Most existing methods predict metabolic states at the pathway level but rarely map reaction-level alterations to their upstream regulators, thereby constraining both interpretability and translational relevance.
> 
> METHODS: We developed MetroSCREEN, a reference-guided computational framework that infers reaction-level metabolic flux propensity and nominates upstream regulators from bulk and single-cell transcriptomes. MetroSCREEN uses a fast enrichment-based procedure to quantify reaction-level metabolic activity. To characterize metabolic regulons, it integrates intrinsic gene-regulatory signals with extrinsic cell-cell interaction cues, then applies a robust multi-evidence ranking scheme to combine these information sources, and finally employs a constraint-based causal discovery module to infer regulatory directionality.
> 
> RESULTS: MetroSCREEN accurately predicts reaction-level metabolic activities and their upstream regulators, as demonstrated using paired transcriptomic-metabolomic datasets from the cancer cell lines. We further validated predicted regulators with in-house single-cell CRISPR screens in PC9 cells targeting metabolic regulators. Applying MetroSCREEN to a pan-cancer single-cell atlas of more than 700,000 fibroblasts and myeloid cells across 36 cancer types, we identified ZNF281 and STAT1 as key regulators of collagen metabolism, which is elevated in extracellular-matrix-associated fibroblasts and macrophages at tumor margins. By contrast, APOE and KLF7 regulate sphingolipid metabolism and antigen presentation in macrophages. Leveraging extensive tumor profiles, MetroSCREEN also delineates metabolic subtypes and regulators associated with patient survival and response to immunotherapy.
> 
> CONCLUSIONS: MetroSCREEN is a robust and scalable approach for characterizing metabolic heterogeneity and pinpointing metabolic regulators at single-cell resolution, unveiling novel antitumor targets for future metabolic interventions. The source codes of MetroSCREEN is available at the Github site https://github.com/wanglabtongji/MetroSCREEN .

> **中文摘要：**
> 背景：代谢重编程是癌症的标志之一；然而，驱动肿瘤微环境中多种细胞类型间代谢异质性的机制仍知之甚少。现有的大多数方法在通路层面预测代谢状态，但很少能将反应层面的改变映射至其上游调控因子，从而限制了解释性与转化相关性。
> 
> 方法：我们开发了 MetroSCREEN，这是一种基于参考引导的计算框架，可通过整体及单细胞转录组推断反应层面的代谢通量倾向，并提名潜在的上游调控因子。MetroSCREEN 采用基于富集分析的快速程序来量化反应层面的代谢活性。为了表征代谢调控组，它整合了内在的基因调控信号与外源性的细胞间相互作用线索，再结合稳健的多证据排序方案以融合这些信息来源，最终利用基于约束的因果发现模块推断调控方向性。
> 
> 结果：借助癌细胞系的配对转录组-代谢组数据集，MetroSCREEN 能够准确预测反应层面的代谢活动及其上游调控因子。我们进一步在靶向代谢调控因子的 PC9 细胞中，通过自建的单细胞 CRISPR 筛选验证了预测的调控因子。将 MetroSCREEN 应用于涵盖 36 种癌症类型、逾 70 万个成纤维细胞及髓系细胞的泛癌单细胞图谱，我们识别出 ZNF281 和 STAT1 是胶原代谢的关键调控因子，该代谢在肿瘤边缘的细胞外基质相关成纤维细胞及巨噬细胞中升高。相比之下，APOE 与 KLF7 调控巨噬细胞中的鞘磷脂代谢与抗原呈递。凭借广泛的肿瘤特征数据，MetroSCREEN 还描绘了与患者生存及免疫治疗反应相关的代谢亚型与调控因子。
> 
> 结论：MetroSCREEN 是一种稳健且可扩展的方法，可在单细胞分辨率下刻画代谢异质性并精准定位代谢调控因子，为未来代谢干预揭示新的抗肿瘤靶点。MetroSCREEN 的源代码可于 Github 地址 https://github.com/wanglabtongji/MetroSCREEN 获取。

### 第二部分 AI 大师评价

本文构建了一个名为 MetroSCREEN 的新型计算框架，通过结合整体与单细胞多组学数据，在反应层面解析癌症微环境中的代谢异质性。该方法创新性地整合基因调控信号、细胞互作线索及因果分析模块，从而实现对代谢通量与上游调控因子的高精度推断。研究在多癌种单细胞图谱中揭示关键代谢调控因子并关联临床预后与免疫应答，展现了突出的生物学意义与潜在转化价值。其局限可能在于模型复杂性及对数据质量的高度依赖。

---

## 4. 维生素C通过5hmC介导的ATF4表观遗传调控增强膀胱癌对顺铂的敏感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41420190)
**期刊：** Clinical epigenetics
**PMID：** 41420190
**DOI：** 10.1186/s13148-025-02011-x

### 第一部分 原文与翻译

**英文原标题：** Vitamin C enhances cisplatin sensitivity in bladder cancer via 5hmC-mediated epigenetic modulation of ATF4.

> **英文摘要：**
> Cisplatin resistance remains a major challenge in the clinical treatment of bladder cancer (BC), and the epigenetic regulation of this resistance, particularly involving 5-hydroxymethylcytosine (5hmC), has not been fully elucidated. Here, we investigated the role of 5hmC and vitamin C (VC) in modulating cisplatin sensitivity in BC. Clinical analyses of 36 BC patients receiving cisplatin-based neoadjuvant chemotherapy showed that reduced 5hmC levels in pre-chemotherapy tumor tissues were significantly associated with cisplatin resistance (CR-BC) and poor prognosis, with low 5hmC correlating with shorter progression-free survival (PFS). In vitro, we established two cisplatin-resistant cell lines (T24-CR, UMUC-3-CR) that exhibited reduced 5hmC compared to parental cells. Treatment with 100 μM VC significantly restored 5hmC levels in CR-BC cells by activating TET enzymes, inhibited cell proliferation, and enhanced cisplatin sensitivity; these effects were abrogated by the TET inhibitor Bobcat339, confirming VC acts in a TET-dependent manner. Mechanistically, genome-wide 850 K methylation array and RNA-seq analyses revealed that VC upregulated methylation specifically at the promoter of ATF4, a downstream effector of the MAPK pathway, thereby downregulating ATF4 expression. ATF4 knockdown in CR-BC cells increasing cisplatin sensitivity, while Bobcat339 reversed VC-induced ATF4 downregulation. In vivo, VC combined with cisplatin significantly inhibited tumor growth in T24-CR xenografts, and co-treatment with ATF4 knockdown further enhanced this effect, accompanied by elevated 5hmC and reduced Ki67 in tumors. Collectively, our findings identify reduced 5hmC as a hallmark of cisplatin-resistant BC and reveal a novel mechanism by which VC enhances cisplatin sensitivity. VC activates TET enzymes to increase 5mC at the ATF4 promoter, downregulating ATF4 and modulating the MAPK pathway. This highlights VC as a potential epigenetic adjuvant to overcome cisplatin resistance in BC.

> **中文摘要：**
> 顺铂耐药仍然是膀胱癌（BC）临床治疗中的主要挑战，而该耐药的表观遗传调控，尤其涉及5-羟甲基胞嘧啶（5hmC）的机制，尚未被充分阐明。本研究探讨了5hmC与维生素C（VC）在调节BC顺铂敏感性中的作用。对36例接受顺铂为基础新辅助化疗的BC患者进行临床分析发现，化疗前肿瘤组织中5hmC水平降低显著与顺铂耐药（CR-BC）及预后不良相关，低5hmC水平与较短的无进展生存期（PFS）相关。在体外，我们建立了两株顺铂耐药细胞系（T24-CR、UMUC-3-CR），其5hmC水平较亲本细胞降低。使用100 μM VC处理CR-BC细胞可通过激活TET酶显著恢复5hmC水平，抑制细胞增殖并增强顺铂敏感性；而TET抑制剂Bobcat339可消除这些效应，证明VC的作用依赖于TET通路。在机制层面，全基因组850 K甲基化芯片和RNA-seq分析显示，VC可特异性上调MAPK通路下游效应因子ATF4启动子的甲基化，从而下调ATF4表达。在CR-BC细胞中敲低ATF4可增强顺铂敏感性，而Bobcat339可逆转VC诱导的ATF4下调。在体内实验中，VC联合顺铂显著抑制T24-CR异种移植瘤的生长，与ATF4敲低联合治疗进一步增强此抗瘤作用，并伴有肿瘤组织中5hmC升高及Ki67下降。综上所述，我们的研究确定了5hmC降低是顺铂耐药性BC的标志，并揭示了VC增强顺铂敏感性的全新机制。VC通过激活TET酶增加ATF4启动子的5mC水平，从而下调ATF4并调控MAPK通路。这提示VC可能作为一种潜在的表观遗传辅药，用以克服BC的顺铂耐药问题。

### 第二部分 AI 大师评价

本研究系统阐明了维生素C通过TET介导的5hmC调控通路增强膀胱癌对顺铂敏感性的分子机制。研究结合临床患者样本分析、体外耐药细胞模型及体内异种移植瘤实验，形成了严谨的多层次验证。结果发现5hmC降低是顺铂耐药的重要表观标志，维生素C可依赖TET活性恢复5hmC水平并抑制ATF4，从而提高药物敏感性。其创新性在于揭示了维生素C作为表观遗传调节剂在耐药肿瘤治疗中的潜在价值。局限性可能在于患者样本量较小，未来仍需临床验证其应用价值。

---

## 5. SGSS05-NS3：一种可激活神经母细胞瘤中 p53 通路的共价型 SETD8 抑制剂

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419951)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41419951
**DOI：** 10.1186/s13046-025-03565-7

### 第一部分 原文与翻译

**英文原标题：** SGSS05-NS3, a covalent SETD8 inhibitor that activates p53 pathway in neuroblastoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究报道了一种名为 SGSS05-NS3 的新型共价型 SETD8 抑制剂，能够在神经母细胞瘤中激活 p53 信号通路。这一工作具有潜在的机制创新性，因为 SETD8 参与多种肿瘤的表观遗传调控。尽管目前尚无摘要提供详细实验数据，但标题暗示该分子可能通过调控肿瘤抑制因子 p53 实现抗肿瘤效应。若结果得到验证，该研究有望为神经母细胞瘤靶向治疗提供新的药物方向。

---

## 6. 新一代CAR-T细胞的设计：利用肿瘤特征以提升疗效

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419929)
**期刊：** Molecular cancer
**PMID：** 41419929
**DOI：** 10.1186/s12943-025-02515-3

### 第一部分 原文与翻译

**英文原标题：** Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究方向聚焦于CAR-T细胞治疗的下一代设计思路，意在通过利用肿瘤微环境及分子特征来增强疗效。尽管正文未提供摘要，但从标题推测，作者可能探讨了基因工程、信号调控或免疫微环境调节等前沿策略。其创新性体现在将肿瘤特征纳入CAR-T细胞功能优化的设计逻辑中，为个体化精准免疫治疗提供思路。然而，实际疗效验证及安全性评估仍需进一步实验与临床研究支持。

---

## 7. 作者更正：由微生物群重编程的磷脂酰胆碱通过外泌体 SerpinB9 介导的 UFM 化在多发性骨髓瘤中使细胞毒性 CD8 T 细胞失活。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419769)
**期刊：** Nature communications
**PMID：** 41419769
**DOI：** 10.1038/s41467-025-67875-2

### 第一部分 原文与翻译

**英文原标题：** Author Correction: Microbiota-reprogrammed phosphatidylcholine inactivates cytotoxic CD8 T cells through UFMylation via exosomal SerpinB9 in multiple myeloma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本文为对先前发表研究的作者更正，原研究探讨了肠道微生物群改变磷脂酰胆碱代谢并通过外泌体 SerpinB9 的 UFM 化作用使细胞毒性 CD8 T 细胞失活的机制，在多发性骨髓瘤免疫逃逸研究中具有重要意义。尽管该文仅为更正声明，但原研究揭示了代谢与免疫调控之间的新联系。其创新点在于提出了一种由微生物群影响免疫细胞功能的分子途径。局限之处在于缺乏更正内容的具体细节，需参考原文获取全面信息。

---

## 8. SPLiCR-seq：一种基于CRISPR的RNA剪接筛选平台，可在内质网应激下发现IRE1α-XBP1信号的新型调控因子

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419745)
**期刊：** Nature communications
**PMID：** 41419745
**DOI：** 10.1038/s41467-025-67633-4

### 第一部分 原文与翻译

**英文原标题：** SPLiCR-seq: A CRISPR-Based Screening Platform for RNA splicing Identifies Novel Regulators of IRE1α-XBP1 Signaling Under ER Stress.

> **英文摘要：**
> RNA splicing is fundamental to cellular function, yet systematic investigation of its complex regulation has been limited by existing methods. Here, we present SPLiCR-seq (SPLicing regulator identification through CRISPR screening), a high-throughput CRISPR screening platform that enables direct measurement of RNA splicing outcomes for pooled genetic perturbations, overcoming limitations of traditional fluorescence-based approaches. Applying SPLiCR-seq to investigate XBP1 splicing during the unfolded protein response (UPR), we conduct targeted and genome-wide screens across diverse cellular contexts, revealing both common and cell-type specific regulators. Notably, we identify GADD34 (PPP1R15A) as a novel modulator of IRE1α-XBP1 signaling, demonstrating that it directly interacts with IRE1α and functions independently of its canonical role in eIF2α dephosphorylation. Pharmacological inhibition of GADD34 using Sephin1 effectively suppressed XBP1 splicing and alleviated CAR-T cell exhaustion in an ex vivo model, leading to enhanced tumor-killing capacity across multiple cancer models. This work not only establishes a powerful new tool for systematically studying RNA splicing regulation but also uncovers a promising therapeutic strategy for improving CAR-T cell immunotherapy through modulation of the IRE1α-XBP1 pathway.

> **中文摘要：**
> RNA剪接是细胞功能的基础，但由于现有方法的限制，对其复杂调控机制的系统性研究仍然不足。本文提出了SPLiCR-seq（通过CRISPR筛选鉴定剪接调控因子的技术），这是一种高通量的CRISPR筛选平台，能够直接测量在混合基因扰动条件下的RNA剪接结果，从而克服传统基于荧光方法的局限性。研究者应用SPLiCR-seq探索未折叠蛋白反应（UPR）过程中XBP1的剪接，开展了靶向性和全基因组范围的筛选，涵盖多种细胞环境，从而揭示了普遍和细胞类型特异的调控因子。值得注意的是，研究确定GADD34（PPP1R15A）是IRE1α-XBP1信号的新型调节因子，显示其可直接与IRE1α相互作用，并独立于其经典的eIF2α去磷酸化作用发挥功能。使用Sephin1药理性抑制GADD34能够有效抑制XBP1剪接，并在离体模型中缓解CAR-T细胞衰竭，从而在多种肿瘤模型中增强肿瘤杀伤能力。本研究不仅建立了一个强大的系统性研究RNA剪接调控的新工具，还揭示了一种通过调控IRE1α-XBP1通路以改善CAR-T细胞免疫治疗的潜在治疗策略。

### 第二部分 AI 大师评价

该研究提出了SPLiCR-seq这一创新的CRISPR筛选平台，实现了RNA剪接结果的直接检测，为系统研究剪接调控提供了新途径。通过对UPR过程中XBP1剪接的分析，作者发现了GADD34作为IRE1α-XBP1信号通路的新型调节因子，揭示其独立于经典功能的作用机制。Sephin1对GADD34的抑制不仅减弱XBP1剪接，还改善了CAR-T细胞功能，显示出潜在的免疫治疗价值。该研究方法学创新显著，但仍需进一步评估在体内模型及临床场景中的转化可行性。

---

## 9. 良性与恶性皮脂腺肿瘤的分子图谱

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419736)
**期刊：** Nature communications
**PMID：** 41419736
**DOI：** 10.1038/s41467-025-66584-0

### 第一部分 原文与翻译

**英文原标题：** The molecular cartography of malignant and benign sebaceous tumours.

> **英文摘要：**
> Sebaceous tumours (STs) are rare skin appendage tumours and include benign sebaceous adenoma (SA) and sebaceoma (SM), malignant extra-ocular sebaceous carcinoma (SC-E) and peri-ocular sebaceous carcinoma (SC-O). Here, an extensive worldwide collection of 286 tumours is deeply characterised, revealing a propensity to develop in the context of a high tumour mutational burden (except in SC-O) which is most frequently associated with mismatch repair deficiency (dMMR), followed by UV-induced damage, POLE/POLD1 mutations, and AID/APOBEC activation signatures. Biallelic TP53 inactivation with concomitant ZNF750 and/or RB1 mutation is seen in SC-E/SC-O. Amplification of 8q (including MYC) is related to SC-O, while amplification of 1q21.3 (including HRNR) and chromosome 20 are shared by SC-O and SC-E, as is deletion of 13q14.3 (where RB1 resides). The most frequently mutated gene is NOTCH1. Extensive fusion gene, expression and molecular cluster analyses provide a molecular portrait of this rare and enigmatic tumour type.

> **中文摘要：**
> 皮脂腺肿瘤（STs）是一类罕见的皮肤附属器肿瘤，包括良性的皮脂腺腺瘤（SA）和皮脂瘤（SM），以及恶性的眼外皮脂腺癌（SC-E）和眶周皮脂腺癌（SC-O）。本研究收集并深度表征了来自全球的286例肿瘤，揭示除SC-O外，这些肿瘤普遍具有较高的突变负荷，且这种特征最常与错配修复缺陷（dMMR）相关，其次为紫外线诱导的损伤、POLE/POLD1突变以及AID/APOBEC活化特征。SC-E和SC-O中可见TP53的双等位基因失活，并伴有ZNF750和/或RB1突变。8q（包括MYC）的扩增与SC-O相关，而1q21.3（包括HRNR）及第20号染色体的扩增在SC-O和SC-E中均存在，同时两者也共享13q14.3（RB1所在区域）的缺失。最常见的突变基因为NOTCH1。通过广泛的融合基因、基因表达和分子聚类分析，本研究为这种罕见且复杂的肿瘤类型提供了详细的分子图谱。

### 第二部分 AI 大师评价

该研究系统描绘了良性与恶性皮脂腺肿瘤的分子特征，建立了全球最大规模的样本组。作者通过全基因组与转录组分析揭示了不同类型皮脂腺肿瘤的突变谱、染色体改变及修复机制缺陷。研究结果强调了TP53、RB1、ZNF750等关键基因和特定拷贝数变异在皮脂腺肿瘤发生中的作用。该工作为理解皮脂腺肿瘤的致病机制与分型提供了坚实的分子依据，尽管其临床验证和功能研究仍需进一步强化。

---

## 10. 抗体类别转换产生的重组连接可分类免疫与 DNA 修复功能障碍

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419734)
**期刊：** Nature communications
**PMID：** 41419734
**DOI：** 10.1038/s41467-025-67206-5

### 第一部分 原文与翻译

**英文原标题：** Recombination junctions from antibody isotype switching classify immune and DNA repair dysfunction.

> **英文摘要：**
> Personalized assessment of immunocompetence and DNA double-strand break (DSB) repair requires methods that are sensitive to genetic and molecular complexity beyond the well-known monogenic disorders. Inspired by decades of research using B cells to study DNA repair processes, here we present SWIBRID (SWItch junction Breakpoint Repertoire IDentification), a tool to systematically profile genomic junctions generated in vivo during antibody class switch recombination (CSR) in B cells. As CSR junctions reflect immune diversity and DNA repair proficiency, SWIBRID detects phenotypic manifestations of deficiencies via a highly scalable, blood-based PCR followed by long-read sequencing and bioinformatic analysis. We show that specific DNA repair defects, including cancer-associated mutations, exhibit distinct CSR junction patterns. Notably, SWIBRID distinguishes different types of DSB repair knockouts and identifies the respective genetic defect in cell lines. In 68 patients, we detect immunodeficiencies and DNA repair defects with high accuracy (area under the curve 0.99 and 0.84, respectively), and identify previously uncharacterized patient groups as well as patient-specific CSR junction signatures. With SWIBRID, we seek to advance the identification of pathogenic defects, support early diagnosis, and address molecular heterogeneity that drives variable clinical outcomes.

> **中文摘要：**
> 针对个体化评估免疫功能和 DNA 双链断裂（DSB）修复的需求，需要能够敏感探测超出单基因缺陷的复杂遗传与分子特征的方法。受数十年来利用 B 细胞研究 DNA 修复机制工作的启发，我们在此提出 SWIBRID（SWItch junction Breakpoint Repertoire IDentification），一种可系统性描绘 B 细胞体内抗体类别转换重组（CSR）过程中产生的基因组连接特征的工具。由于 CSR 连接反映了免疫多样性与 DNA 修复能力，SWIBRID 通过一种高度可扩展的基于血液的 PCR 技术，结合长读长测序与生物信息学分析，检测功能缺陷的表型表现。我们展示了特定的 DNA 修复缺陷（包括与癌症相关的突变）呈现出独特的 CSR 连接模式。值得注意的是，SWIBRID 能区分不同类型的 DSB 修复敲除模型，并识别细胞系中相应的遗传缺陷。在 68 名患者样本中，我们以高精度检测到免疫缺陷与 DNA 修复缺陷（曲线下面积分别为 0.99 和 0.84），并识别出此前未表征的患者群体及个体特异性的 CSR 连接特征。借助 SWIBRID，我们旨在推动致病性缺陷的识别，支持早期诊断，并应对导致临床结局差异的分子异质性问题。

### 第二部分 AI 大师评价

本研究提出了 SWIBRID 平台，利用抗体类别转换的基因组连接信息系统性评估免疫功能及 DNA 修复能力。方法结合血液来源的 PCR、长读长测序与生物信息学分析，实现对体内重组断点的全景化描绘。结果显示 SWIBRID 能高精度区分免疫与 DNA 修复缺陷，并揭示癌症相关突变的特征性连接模式。该工具具备显著的创新性，为免疫缺陷早期诊断和分子机制研究提供了新途径，但仍需在更大人群与多疾病背景下验证其临床适用性。

---

## 11. MIDAS：用于宿主-病原体综合分析的快速多重分子分型技术

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419730)
**期刊：** Nature communications
**PMID：** 41419730
**DOI：** 10.1038/s41467-025-67391-3

### 第一部分 原文与翻译

**英文原标题：** MIDAS: rapid, multiplexed molecular profiling for integrated host-pathogen analysis.

> **英文摘要：**
> Addressing the need for integrated molecular analysis in complex infectious conditions requires technologies that rapidly quantify both pathogens and host responses. This is particularly relevant in sepsis research, where existing tools typically measure either microbial or host biomarkers. Here, we present MIDAS (Multiplexed Intelligent Diffraction Analysis System), a proof-of-concept platform that integrates shape-encoded hydrogel particles with lens-free diffraction imaging and deep learning-based analysis to enable simultaneous quantification of bacterial RNA and inflammatory proteins in a single system optimized for potential point-of-care use. The assay completes multiplexed measurements in under 4 h, significantly faster than standard culture workflows ( ~ 20-40 h). Beyond spiked studies, MIDAS is evaluated using specimens from a clinically relevant porcine sepsis model, showing high concordance with culture, qPCR and ELISA. Although further clinical validation is required, this flexible platform may support the development of accessible host-pathogen profiling tools with broad applications in healthcare, agriculture, food safety, and beyond.

> **中文摘要：**
> 在复杂感染性疾病中实现综合分子分析的需求，需要能够快速定量病原体和宿主反应的技术。这在脓毒症研究中尤为重要，因为现有工具通常只测量微生物或宿主生物标志物。本文介绍了 MIDAS（多重智能衍射分析系统），这是一种概念验证平台，将形状编码的水凝胶颗粒与无透镜衍射成像和基于深度学习的分析相结合，实现了在单一系统中同时定量细菌 RNA 和炎症蛋白的能力，该系统已针对潜在的即时检测应用进行了优化。该检测可在 4 小时内完成多重测定，速度显著快于标准培养流程（约 20–40 小时）。除掺样研究外，研究者还使用具有临床相关性的猪脓毒症模型样本对 MIDAS 进行了评估，结果显示其与培养、qPCR 和 ELISA 具有高度一致性。尽管仍需进一步的临床验证，这一灵活的平台有望支持可及性宿主-病原体分型工具的开发，并在医疗、农业、食品安全等领域实现广泛应用。

### 第二部分 AI 大师评价

该研究旨在开发一种整合宿主与病原体分子分析的快速检测平台 MIDAS，通过形状编码水凝胶、衍射成像与深度学习的融合，实现细菌 RNA 与炎症蛋白的多重定量。其检测速度远快于传统培养方法，并在动物模型中表现出良好的准确性与一致性。创新点在于仪器系统高度集成、分析通量高且时间效率显著。局限性在于尚需更多临床样本验证以评估其广泛适用性。

---

## 12. 随机性有助于解释凋亡过程中少数与多数线粒体外膜通透化（MOMP）现象。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419664)
**期刊：** Cell death & disease
**PMID：** 41419664
**DOI：** 10.1038/s41419-025-08258-9

### 第一部分 原文与翻译

**英文原标题：** Stochasticity contributes to explaining minority and majority MOMP during apoptosis.

> **英文摘要：**
> Apoptosis dysfunction is linked to diseases like cancer and neurodegenerative disorders. A key event during apoptosis is mitochondrial outer membrane permeabilization (MOMP), which typically proceeds in a rapid all-or-none fashion. If MOMP occurs only in a subset of mitochondria (minority MOMP), it can be sublethal and contribute to tumorigenesis and cancer progression. Similarly, individual mitochondria escaping widespread MOMP (majority MOMP) can allow cancer cells to recover if apoptosis execution fails. How such heterogeneities in mitochondrial MOMP responsiveness arise within cells is incompletely understood. In particular, whether stochasticity in subcellular protein distributions and interactions across cytosol and mitochondria can realistically contribute to mitochondrial MOMP heterogeneity has not yet been studied. To assess this, we sequentially built and experimentally parameterized a particle-based, cell-sized model including cytosolic and mitochondrial compartments, and that featured a reduced interactome of MCL-1, BAK and tBID. High-performance computing enabled cell-scale simulations of protein distributions and interactions to understand how and under which conditions stochasticity could contribute to heterogeneity in MOMP susceptibility. Our results show that stochastic effects strongly predispose sub-pools of fragmented mitochondria to MOMP under low apoptotic stress. At higher apoptotic stress, fractions of small mitochondria were more likely to escape MOMP than large mitochondria. Retrospective quantification of mitochondrial sizes in experimental scenarios of minority and majority MOMP confirmed these findings. We therefore conclude that stochasticity substantially contributes to enabling small or fragmented mitochondria to undergo MOMP in minority MOMP scenarios and to escape MOMP in majority MOMP scenarios.

> **中文摘要：**
> 凋亡功能障碍与癌症和神经退行性疾病等多种疾病相关。凋亡过程中的一个关键事件是线粒体外膜通透化（MOMP），该过程通常以快速的“全或无”方式发生。如果 MOMP 仅发生在部分线粒体中（少数 MOMP），其可能是亚致死性的，并促进肿瘤发生和癌症进展。同样，若个别线粒体逃脱广泛的 MOMP（多数 MOMP），在凋亡执行失败时可能使癌细胞得以恢复。目前尚未完全理解细胞内线粒体 MOMP 反应性异质性是如何产生的。特别是，胞质和线粒体间亚细胞蛋白分布及相互作用中的随机性是否现实地导致线粒体 MOMP 异质性，尚未被研究。为评估这一点，我们逐步构建并进行实验参数化的、基于粒子的细胞级模型，其中包含胞质和线粒体区室，并包括 MCL-1、BAK 和 tBID 的简化互作网络。借助高性能计算，我们在细胞尺度上模拟了蛋白质的分布与相互作用，以理解随机性如何及在何种条件下影响 MOMP 易感性的异质性。结果显示，在低凋亡应激下，随机效应显著促使线粒体碎片的子群体易于发生 MOMP；而在高凋亡应激下，小线粒体群体比大线粒体更可能逃逸 MOMP。对少数与多数 MOMP 实验情景下线粒体大小的回顾性定量分析验证了这些发现。因此，我们得出结论：随机性在少数 MOMP 情景下显著促进小型或碎片化线粒体经历 MOMP，在多数 MOMP 情景下有助于其逃避 MOMP。

### 第二部分 AI 大师评价

该研究旨在探讨细胞内随机性在凋亡过程中不同线粒体外膜通透化（MOMP）模式形成中的作用。作者基于 MCL-1、BAK 与 tBID 的互作网络，建立了粒子级、细胞尺度的随机模型，并利用高性能计算进行动态模拟。结果揭示，在不同凋亡应激水平下，随机性会导致线粒体大小及分布上的异质性，从而影响 MOMP 的发生与逃逸。这一发现为解释少数与多数 MOMP 现象提供了物理与分子层面的机制依据，但模型仍较为简化，需结合更多生理实验验证其普适性。

---

## 13. TIGIT 作为靶点在 BCMA-CAR-T 治疗后增强疗效并缓解多发性骨髓瘤 T 细胞衰竭的临床前评估

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419632)
**期刊：** Cell death & disease
**PMID：** 41419632
**DOI：** 10.1038/s41419-025-08203-w

### 第一部分 原文与翻译

**英文原标题：** Preclinical evaluation of TIGIT as a target to enhance efficacy and mitigate T cell exhaustion in multiple myeloma following BCMA-CAR-T therapy.

> **英文摘要：**
> Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has achieved notable efficacy in relapsed/refractory multiple myeloma (RRMM), yet most patients eventually relapse, highlighting the need to elucidate mechanisms of resistance. In this study, we investigated the role of TIGIT in resistance to BCMA-CAR-T therapy. Tumor-infiltrating T cells from RRMM patients receiving BCMA-CAR-T therapy were analyzed by single-cell RNA sequencing, and immune checkpoint expression was further assessed by flow cytometry. Functional assays, including luciferase-based cytotoxicity, CD107a degranulation, CFSE proliferation, and CD45RO/CD62L phenotyping, were performed to investigate the effects of TIGIT inhibition through knockout or anti-TIGIT monoclonal antibodies (mAbs). In a humanized immune cell-reconstituted mouse model, TIGIT blockade was further evaluated for its effects on tumor growth and T cell exhaustion. T cells from patients with early relapse exhibited higher TIGIT expression than those from patients with durable responses, and elevated TIGIT levels were correlated with increased tumor burden and poor prognosis. While TIGIT blockade exerted limited effects on CAR-T function in vitro, it markedly enhanced CAR-T proliferation, mitigated T cell exhaustion, and improved antitumor efficacy in vivo, particularly when mediated by anti-TIGIT mAbs. Transcriptomic profiling further revealed that TIGIT modulates CAR-T activity by regulating cytokines and chemokines pathways and T cell activation, findings that were preliminarily validated by functional assays. Collectively, these findings identify TIGIT as a critical regulator of resistance to BCMA-CAR-T therapy and highlight TIGIT blockade as a promising strategy to enhance CAR-T efficacy and overcome relapse in multiple myeloma.

> **中文摘要：**
> 针对 B 细胞成熟抗原（BCMA）的嵌合抗原受体 T 细胞（CAR-T）治疗在复发/难治性多发性骨髓瘤（RRMM）中取得了显著疗效，但大多数患者最终仍然复发，这凸显了阐明耐药机制的必要性。本研究探讨了 TIGIT 在 BCMA-CAR-T 治疗耐药中的作用。从接受 BCMA-CAR-T 治疗的 RRMM 患者中提取的肿瘤浸润 T 细胞通过单细胞 RNA 测序进行分析，并通过流式细胞术进一步评估免疫检查点的表达。采用基于荧光素酶的细胞毒性实验、CD107a 脱颗粒实验、CFSE 增殖实验和 CD45RO/CD62L 表型分析等功能性实验，研究通过敲除或使用抗 TIGIT 单克隆抗体（mAbs）抑制 TIGIT 的作用。在人源化免疫细胞重建的小鼠模型中，进一步评估 TIGIT 阻断对肿瘤生长和 T 细胞衰竭的影响。早期复发患者的 T 细胞显示出比长期应答患者更高的 TIGIT 表达，且 TIGIT 水平升高与肿瘤负荷增加和预后不良相关。尽管 TIGIT 阻断在体外对 CAR-T 功能的影响有限，但在体内显著增强了 CAR-T 的增殖，减轻了 T 细胞衰竭，并改善了抗肿瘤疗效，尤其是在抗 TIGIT 单抗介导下效果更为明显。转录组学分析进一步表明，TIGIT 通过调控细胞因子和趋化因子通路及 T 细胞活化来调节 CAR-T 活性，这些发现通过功能实验得到了初步验证。总体而言，这些结果确认了 TIGIT 是介导 BCMA-CAR-T 治疗耐药的关键调节因子，并提示 TIGIT 阻断是一种有前景的策略，可增强 CAR-T 疗效并克服多发性骨髓瘤的复发。

### 第二部分 AI 大师评价

本研究旨在揭示 TIGIT 在 BCMA-CAR-T 治疗多发性骨髓瘤耐药中的作用机制。作者利用单细胞测序、流式细胞术及多种功能性实验相结合的方法，系统评估 TIGIT 阻断对 CAR-T 功能和 T 细胞衰竭的影响。结果显示，抑制 TIGIT 可显著增强 CAR-T 细胞的增殖与抗肿瘤活性，并延缓复发进程。该研究创新性地将 TIGIT 通路与 CAR-T 疗法的耐药机制相联系，为优化免疫治疗策略提供了实验依据，但其临床转化仍需进一步验证。

---

## 14. 基于BET抑制剂的联合疗法靶向MECOM重排型急性髓系白血病中的新型依赖机制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419608)
**期刊：** Leukemia
**PMID：** 41419608
**DOI：** 10.1038/s41375-025-02842-w

### 第一部分 原文与翻译

**英文原标题：** BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.

> **英文摘要：**
> MECOM rearrangement in AML involves either inv(3)(q21;q26.2) or t(3;3)(q21;q26.2), where the dislocated GATA2 enhancer drives overexpression of the transcriptional regulator EVI1, causes concomitant GATA2 repression, and promotes AML progression, aggressive phenotype and therapy refractoriness. Treatment with BET protein inhibitor (BETi) induces in vitro and in vivo efficacy in MECOM-r AML cells. Utilizing an unbiased, high-throughput drug screen, focused on mechanistically-annotated drugs, we identified BRD4, PIK3CA, mTOR, BCL-xL and XIAP as dependencies in the MECOM-r AML cells. Monotherapy with mivebresib (BETi), dactolisib (PI3K/mTORi) and LCL161 (IAPi) dose-dependently induced greater lethality in PD MECOM-r versus non-MECOM-r AML cells. RNA-Seq and/or mass spectrometry analyses revealed that treatment with mivebresib or dactolisib downregulated MYC-targets and cell-cycle gene-sets whereas CyTOF and Western analyses also demonstrated reduction in the protein levels of EVI1, c-Myb, c-Myc in MECOM-r AML cells. Combination of mivebresib and dactolisib or LCL161 synergistically induced apoptosis. In a MECOM-r AML PDX model, mivebresib with dactolisib or LCL161, was superior to monotherapy or vehicle in reducing AML burden and increasing mouse survival. These findings highlight that cotreatment with BETi and PI3K/mTOR or IAP inhibitor exerts superior in vitro and in vivo efficacy in MECOM-r AML cells and support further evaluation of these BETi-based combinations.

> **中文摘要：**
> 在急性髓系白血病（AML）中，MECOM重排涉及inv(3)(q21;q26.2)或t(3;3)(q21;q26.2)，其中移位的GATA2增强子驱动转录调控因子EVI1的过度表达，同时导致GATA2的抑制，从而促进AML的进展、侵袭性表型及治疗耐受性。使用BET蛋白抑制剂（BETi）治疗可在体外和体内对MECOM重排型AML细胞产生显著疗效。通过一项非偏倚的高通量药物筛选，聚焦于具有机制注释的药物，研究者鉴定出BRD4、PIK3CA、mTOR、BCL-xL和XIAP是MECOM重排型AML细胞的依赖分子。单药治疗使用mivebresib（BETi）、dactolisib（PI3K/mTORi）和LCL161（IAPi）在MECOM重排型细胞中较非重排型AML细胞呈剂量依赖性地诱导更强杀伤作用。RNA测序和/或质谱分析显示，mivebresib或dactolisib处理下，MYC靶基因及细胞周期相关基因集下调，而CyTOF和Western blot分析亦证实MECOM重排型AML细胞中EVI1、c-Myb和c-Myc蛋白水平降低。mivebresib与dactolisib或LCL161联合应用可协同诱导凋亡。在MECOM重排型AML患者来源异种移植（PDX）模型中，mivebresib联合dactolisib或LCL161在减少白血病负荷与延长小鼠存活方面优于单药或对照组。这些结果表明，BETi与PI3K/mTOR或IAP抑制剂联合治疗在MECOM重排型AML细胞中具有更优的体内外疗效，并支持对这些基于BETi的联合方案开展进一步研究。

### 第二部分 AI 大师评价

该研究聚焦于MECOM重排型急性髓系白血病的分子依赖机制，运用高通量筛选、转录组及蛋白组分析揭示了关键依赖通路。研究发现BET抑制剂与PI3K/mTOR或IAP抑制剂的组合能够协同诱导凋亡并在小鼠模型中显著降低白血病负荷。该工作在靶向复杂基因重排AML的精准联合治疗策略上具有创新性，为临床转化提供了新的方向。然而，仍需更大样本和临床验证以确认其长期疗效与安全性。

---

## 15. 针对急性髓系白血病干细胞的 IL-1/IRAK1/4 信号通路进行靶向治疗：治疗后及复发阶段的研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419607)
**期刊：** Leukemia
**PMID：** 41419607
**DOI：** 10.1038/s41375-025-02816-y

### 第一部分 原文与翻译

**英文原标题：** Targeting IL-1/IRAK1/4 signaling in acute myeloid leukemia stem cells following treatment and relapse.

> **英文摘要：**
> Therapies for acute myeloid leukemia (AML) face formidable challenges due to relapse, often driven by leukemia stem cells (LSCs). Strategies targeting LSCs hold promise for enhancing outcomes, yet paired comparisons of functionally defined LSCs at diagnosis and relapse remain underexplored. We present transcriptome analyses of functionally defined LSC populations at diagnosis and relapse, revealing significant alterations in IL-1 signaling. Interleukin-1 receptor type I (IL1R1) and interleukin-1 receptor accessory protein (IL1RAP) were notably upregulated in leukemia stem and progenitor cells at both diagnosis and relapse. Knockdown of IL1R1 and IL1RAP reduced the clonogenicity and/or engraftment of primary human AML cells. In leukemic MLL-AF9 mice, Il1r1 knockout reduced LSC frequency and extended survival. To target IL-1 signaling at both diagnosis and relapse, we developed UR241-2, a novel interleukin-1 receptor-associated kinase 1 and 4 (IRAK1/4) inhibitor. UR241-2 robustly suppressed IL-1/IRAK1/4 signaling, including NF-κB activation and phosphorylation of p65 and p38, following IL-1 stimulation. UR241-2 selectively inhibited LSC clonogenicity in primary human AML cells at both diagnosis and relapse, while sparing normal hematopoietic stem and progenitor cells. It also reduced AML engraftment in leukemic mice. Our findings highlight the therapeutic potential of UR241-2 in targeting IL-1/IRAK1/4 signaling to eradicate LSCs and improve AML outcomes.

> **中文摘要：**
> 急性髓系白血病（AML）的治疗因复发而面临严峻挑战，这种复发通常由白血病干细胞（LSCs）驱动。针对 LSC 的治疗策略有望改善疗效，但目前对功能性定义的诊断期与复发期 LSC 的成对比较仍研究不足。我们对诊断期和复发期的功能性 LSC 群体进行转录组分析，发现 IL-1 信号通路存在显著变化。白介素-1 受体 I 型（IL1R1）和白介素-1 受体辅链蛋白（IL1RAP）在诊断期和复发期的白血病干/祖细胞中均明显上调。敲低 IL1R1 和 IL1RAP 可降低人原代 AML 细胞的克隆形成能力和/或植入能力。在白血病 MLL-AF9 小鼠模型中，Il1r1 的敲除可减少 LSC 频率并延长生存期。为了在诊断期和复发期同时靶向 IL-1 信号通路，我们开发了 UR241-2，这是一种新型的白介素-1 受体相关激酶 1 和 4（IRAK1/4）抑制剂。UR241-2 可强效抑制 IL-1/IRAK1/4 信号通路，包括 IL-1 刺激后 NF-κB 活化及 p65 和 p38 的磷酸化。UR241-2 能选择性抑制人原代 AML 细胞在诊断期和复发期的 LSC 克隆形成能力，同时保留正常造血干/祖细胞功能。此外，它还能降低白血病小鼠的 AML 植入率。我们的研究结果表明，UR241-2 通过靶向 IL-1/IRAK1/4 信号通路，有望清除 LSC 并改善 AML 预后，具有潜在的治疗价值。

### 第二部分 AI 大师评价

本研究关注急性髓系白血病在治疗和复发阶段中白血病干细胞的关键生存信号通路 IL-1/IRAK1/4。作者通过功能性 LSC 的转录组分析揭示 IL-1 信号通路在疾病演进中的重要作用，并验证 IL1R1 与 IL1RAP 的上调与干细胞活性增强密切相关。新开发的 IRAK1/4 抑制剂 UR241-2 展示了选择性抑制 LSC 而不损伤正常造血干细胞的优异特性，说明其具有较高的治疗特异性和转化潜力。研究的创新性在于首次在诊断与复发两个阶段系统比较 LSC 的信号差异，并提出了可行的靶向干预策略，但仍需进一步验证其临床安全性与长期疗效。

---

## 16. 德国慢性髓性白血病患者的治疗期望与目标：以患者为中心的视角

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419606)
**期刊：** Leukemia
**PMID：** 41419606
**DOI：** 10.1038/s41375-025-02826-w

### 第一部分 原文与翻译

**英文原标题：** Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective.

> **英文摘要：**
> Chronic myeloid leukemia (CML) is a chronic condition with excellent long-term survival under tyrosine kinase inhibitor (TKI) therapy. However, patient priorities regarding treatment goals and quality of life remain insufficiently understood. We conducted a nationwide online survey among German CML patients in collaboration with the German CML Alliance and patient organizations to assess treatment goals at diagnosis, during therapy, and in the treatment-free remission phase. The questionnaire included validated measures of treatment satisfaction, fear of progression, and quality-of-life priorities, supplemented by newly developed items. Between November 2024 and February 2025, 582 patients (median age 56 years, 48.8% female) completed the survey. Overall TKI tolerability was rated positively (median 4/5), particularly in first-line therapy and among patients with shorter disease duration, whereas long-term survivors reported more daily-life limitations. Younger patients ( < 45 years) emphasized fertility, sexuality, and work-related concerns, while older patients prioritized tolerability, independence, and mental health. Treatment history shaped expectations: those with discontinuation experience were more willing to accept adverse effects for the prospect of remission. Overall, patient priorities diverged between achieving deep molecular response and maintaining optimal tolerability. Integrating patient-reported preferences into shared decision-making may enhance satisfaction, adherence, and long-term outcomes of patients with CML.

> **中文摘要：**
> 慢性髓性白血病（CML）是在酪氨酸激酶抑制剂（TKI）治疗下具有极佳长期生存率的慢性疾病。然而，关于患者在治疗目标和生活质量方面的优先事项仍缺乏充分了解。我们与德国CML联盟及患者组织合作，在德国CML患者中开展了一项全国性在线调查，以评估患者在确诊时、治疗过程中及治疗停药缓解期的治疗目标。问卷包含已验证的治疗满意度、进展恐惧及生活质量优先事项等量表，并补充了新开发的项目。在2024年11月至2025年2月期间，共有582名患者（中位年龄56岁，女性占48.8%）完成调查。总体而言，TKI的耐受性被正面评价（中位值4/5），尤其是在一线治疗阶段及病程较短的患者中，而长期存活者报告了更多日常生活受限情况。年龄较小的患者（<45岁）更关注生育、性健康及工作相关问题，而年长患者则更重视耐受性、独立性及心理健康。既往治疗史影响了患者的期望：有停药经历者更愿意为缓解的可能而接受不良反应。总体而言，患者的优先事项在实现深度分子应答与维持最佳耐受性之间存在差异。将患者报告的偏好纳入共同决策过程，可能有助于提升CML患者的满意度、依从性及长期疗效。

### 第二部分 AI 大师评价

本研究旨在以患者为中心，系统探索德国CML患者在不同治疗阶段的目标与期望。通过全国性在线问卷，研究团队揭示了不同年龄、病程及治疗经历患者在疗效、耐受性及生活质量方面的优先关注点。结果显示，年轻与年长患者的关注焦点存在代际差异，治疗经历亦塑造期望与妥协意愿。该研究的创新之处在于将患者观点系统纳入治疗目标评估，为未来CML个体化管理及共同决策提供了实证依据，但其基于自报问卷的设计可能导致选择偏倚。

---

## 17. 通过测序破解谜团（SIRIUS）：利用全基因组和全转录组测序揭示血液系统疾病的诊断之钥

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419605)
**期刊：** Leukemia
**PMID：** 41419605
**DOI：** 10.1038/s41375-025-02820-2

### 第一部分 原文与翻译

**英文原标题：** Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.

> **英文摘要：**
> In the rapidly evolving field of hematology, the diagnosis of leukemias and lymphomas poses major challenges, despite significant genetic advancements. Although established diagnostic methods comprise a multidisciplinary approach and are considered gold standard, in some cases they fall short in conclusively identifying hematological neoplasms. In this context, the current SIRIUS study (NCT05046444) delves into the potential of whole genome sequencing (WGS) and whole transcriptome sequencing (WTS) to bridge diagnostic gaps. By analyzing 106 patients with an unclear diagnosis or clinical condition following gold standard diagnostics, our study demonstrates that WGS and WTS can uncover a broader range of somatic alterations, including rare single-nucleotide variants (SNVs), small copy number variations (CNVs), and aberrant gene expression patterns not detected by conventional diagnostics. WGS and WTS provided additional diagnostic insights in 25% of cases, suggesting their value not only in enhancing diagnostic accuracy but also in contributing to more informed prognostic assessments and personalized treatment strategies. Therefore, our study underscores the importance of integrating WGS and WTS into the diagnostic toolbox for hematological neoplasms. This approach promises not only to improve patient outcomes but also to do so in a manner that is both financially sustainable and ethically sound.

> **中文摘要：**
> 在迅速发展的血液学领域，即使遗传学已取得显著进展，白血病和淋巴瘤的诊断仍面临巨大挑战。尽管现有的诊断方法采用多学科联合方式，并被视为金标准，但在某些情况下，仍无法确切识别血液系统肿瘤。在此背景下，当前的 SIRIUS 研究（NCT05046444）探讨了全基因组测序（WGS）和全转录组测序（WTS）在弥合诊断缺口方面的潜力。通过分析 106 名在金标准诊断后仍存在诊断或临床状况不明确的患者，本研究表明 WGS 和 WTS 能够揭示更广泛的体细胞改变，包括罕见的单核苷酸变异（SNV）、小的拷贝数变异（CNV）以及常规诊断未检测到的异常基因表达模式。WGS 和 WTS 在 25% 的病例中提供了额外的诊断见解，提示其不仅有助于提高诊断准确性，还能促进更有依据的预后评估和个体化治疗策略。因此，我们的研究强调了将 WGS 和 WTS 纳入血液系统肿瘤诊断工具箱的重要性。这一方法有望以财政可持续且符合伦理的方式改善患者预后。

### 第二部分 AI 大师评价

该研究旨在解决血液系统恶性肿瘤诊断中的未解难题，通过在传统金标准诊断后应用全基因组和全转录组测序，为模糊病例提供更深层的分子线索。研究结果显示，这一组合技术在四分之一的案例中带来了新的诊断结果，揭示了常规手段无法发现的变异与基因表达异常。研究的创新之处在于强调“多组学整合诊断”的价值，为精准分型与治疗决策提供依据。局限之处在于样本量相对有限及成本因素的考虑，但其临床推广潜力和策略性意义值得关注。

---

## 18. 接受 BCMA CAR‑T 治疗的多发性骨髓瘤患者中血清学与 PET/CT 反应动力学的预后价值

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419604)
**期刊：** Leukemia
**PMID：** 41419604
**DOI：** 10.1038/s41375-025-02819-9

### 第一部分 原文与翻译

**英文原标题：** Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究关注 BCMA 靶向 CAR‑T 细胞治疗多发性骨髓瘤后的疗效监测，探讨血清学指标和 PET/CT 影像学反应速度作为预后判断工具的潜力。虽然尚无摘要细节，但标题表明作者可能分析了动态反应参数与疾病结局之间的相关性。这种多模态响应动力学研究有助于优化疗效评估标准，提升患者风险分层的精准度。创新性较高，但仍需通过具体数据验证其实用性与普适性。

---

## 19. TP53突变复杂核型急性髓系白血病的病因学研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419603)
**期刊：** Leukemia
**PMID：** 41419603
**DOI：** 10.1038/s41375-025-02835-9

### 第一部分 原文与翻译

**英文原标题：** Etiology of TP53 mutated complex karyotype acute myeloid leukemia.

> **英文摘要：**
> SCHEMATIC VIEW OF THE DEVELOPMENT OF CK-AML DRIVEN BY THE TP53 ABSENCE.: The occurrence of the first, often dominant negative TP53 mutation is quickly followed by the loss of the second TP53 allele and numerous further chromosomal aberrations.

> **中文摘要：**
> 由TP53缺失驱动的复杂核型急性髓系白血病（CK-AML）发展的示意图：首次出现的、通常具有显性负效应的TP53突变之后，很快会发生第二个TP53等位基因的丢失，以及大量其他染色体畸变的出现。

### 第二部分 AI 大师评价

本研究聚焦于由TP53突变驱动的复杂核型急性髓系白血病的发生机制。通过解析TP53首次突变、等位基因丢失及随后的染色体异常，揭示了TP53功能缺失在CK-AML形成中的核心作用。文章为理解基因不稳定性与疾病演进的因果关系提供了重要线索，尤其对早期分子事件有启示意义。但目前分析仍属模式化推演，需进一步的实验与临床数据验证。

---

## 20. 自体干细胞移植中克隆性造血动力学及细胞对应激毒性的反应动态研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419602)
**期刊：** Leukemia
**PMID：** 41419602
**DOI：** 10.1038/s41375-025-02823-z

### 第一部分 原文与翻译

**英文原标题：** Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.

> **英文摘要：**
> Autologous stem cell transplantation (ASCT) involves harvesting hematopoietic stem and progenitor cells (HSPCs) prior to chemotherapy and subsequent repopulation of the bone marrow. This process imposes a bottleneck, providing a framework to dissect the unresolved short- and long-term clonal dynamics during hematopoietic reconstitution. By integrating bulk error-corrected targeted sequencing of clonal hematopoiesis (CH)-associated genes with mitochondrial single-cell Assay for Transposase-Accessible Chromatin sequencing (mtscATAC-seq), we characterized mutational trajectories in frequently altered hematological genes and traced clonal evolution through somatic mitochondrial DNA variants, revealing post-transplant cellular heterogeneity and clonal architecture. Among 60 patients (multiple myeloma, n = 51; non-Hodgkin lymphoma, n = 6; Hodgkin lymphoma, n = 3), CH-associated mutations were identified in 53% pre-ASCT, predominantly involving DNMT3A. A transient increase in mutation counts and gene diversity occurred 10-25 days post-ASCT, with a gradual clonal expansion two years post-transplantation. Tandem ASCT amplified clonal complexity, with a twofold increase in mutation count and gene-level diversity, while preserving clonal trajectories across both transplant courses. Mitochondrial single-cell profiling in longitudinal samples of 3 patients showed patient-specific immune reconstitution and clonal dynamics, with balanced multilineage output from graft HSPCs. Collectively, our findings provide a firsthand comprehensive view of ASCT-induced clonal dynamics and immune reconstitution, paving the way for targeted gene-specific post-transplant monitoring.

> **中文摘要：**
> 自体干细胞移植（ASCT）包括在化疗前采集造血干细胞和祖细胞（HSPCs），随后用于骨髓再植复。该过程形成了一个瓶颈，提供了一个框架，用于解析造血重建过程中尚未解决的短期和长期克隆动态。通过整合针对克隆性造血（CH）相关基因的批量误差校正靶向测序与线粒体单细胞染色质可及性测序（mtscATAC-seq），我们描绘了常见血液学基因的突变轨迹，并通过体细胞线粒体DNA变异追踪克隆演化，从而揭示了移植后细胞异质性和克隆结构。在60例患者中（多发性骨髓瘤n=51；非霍奇金淋巴瘤n=6；霍奇金淋巴瘤n=3），ASCT前有53%检测到CH相关突变，主要涉及DNMT3A。移植后10–25天突变数量和基因多样性出现短暂增加，且移植后两年出现逐步的克隆扩增。串联ASCT增强了克隆复杂性，使突变数和基因水平多样性增加两倍，同时在两次移植过程中保持了克隆轨迹的连续性。对3例患者的纵向线粒体单细胞谱分析显示，存在患者特异性的免疫重建与克隆动态，移植物来源的HSPCs表现出平衡的多系输出。总体而言，本研究首次全面揭示了ASCT诱导的克隆动力学及免疫重建特征，为针对特定基因的移植后监测奠定了基础。

### 第二部分 AI 大师评价

本研究系统揭示了自体干细胞移植后造血系统的克隆动力学演化与免疫重建过程。研究创新性地结合批量误差校正测序和线粒体单细胞染色质可及性测序，追踪突变轨迹与克隆演化。结果发现移植后克隆复杂度短暂上升并在长期逐步扩增，且DNMT3A突变最为常见，串联移植进一步放大克隆多样性。该研究为基于基因的移植后监测提供了重要依据，但样本量及长期随访仍需扩大验证。

---

## 21. 长链非编码RNA LENT与DHX36的相互作用调控翻译并抑制黑色素瘤中的自噬

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419583)
**期刊：** Cell death & disease
**PMID：** 41419583
**DOI：** 10.1038/s41419-025-08296-3

### 第一部分 原文与翻译

**英文原标题：** Interaction of lncRNA LENT with DHX36 regulates translation and suppresses autophagy in melanoma.

> **英文摘要：**
> The melanocyte lineage-determining Microphthalmia-associated transcription factor (MITF) drives proliferation and survival of melanocytic melanoma cells through regulation of both coding genes and long non-coding RNAs (LncRNAs). Here we characterize LINC00520 (hereafter called LncRNA ENhancer of Translation, LENT) regulated by MITF and strongly expressed in melanocytic melanoma cells. LENT is essential for the proliferation and survival of cultured melanocytic melanoma cells and xenograft tumors. LENT interacts with the G4 quadruplex resolvase DHX36, and both associate with the ribosome in the 80S and light polysome fractions. LENT modulates DHX36 association with a collection of mRNAs regulating their engagement with polysomes and fine-tuning their subsequent translation. These mRNAs encode proteins involved in endoplasmic reticulum (ER) and mitochondrial homeostasis as well as autophagy. Consequently, LENT silencing leads to extensive autophagy and mitophagy, compromised oxidative metabolic capacity, accompanied by an accumulation and mis-localization of mitochondrial proteins leading to proteotoxic stress and apoptosis. The LENT-DHX36 axis therefore fine-tunes translation of proteins involved in ER and mitochondrial homeostasis, suppressing autophagy and promoting survival and proliferation of melanoma cells.

> **中文摘要：**
> 黑素细胞谱系决定因子——小眼相关转录因子（MITF），通过调控编码基因和长链非编码RNA（LncRNA），驱动黑素瘤细胞的增殖和存活。本研究鉴定了受MITF调控并在黑素瘤细胞中高表达的LINC00520（以下简称翻译增强长链非编码RNA，LENT）。LENT对于培养的黑素瘤细胞及异种移植瘤的增殖和存活至关重要。LENT与G4四链体解旋酶DHX36相互作用，且两者共同存在于80S核糖体及轻多核糖体组分中。LENT调节DHX36与一组mRNA的结合，从而影响这些mRNA在多核糖体中的参与度，精细调控其后续翻译。这些mRNA编码参与内质网（ER）和线粒体稳态以及自噬过程的蛋白。因而，沉默LENT会导致广泛的自噬和线粒体自噬，削弱氧化代谢能力，并伴随线粒体蛋白的积累和定位异常，引发蛋白毒性应激及细胞凋亡。因此，LENT-DHX36轴通过精细调控与内质网和线粒体稳态相关蛋白的翻译，抑制自噬，从而促进黑色素瘤细胞的生存和增殖。

### 第二部分 AI 大师评价

本文揭示了由MITF调控的长链非编码RNA LENT在黑色素瘤中的关键作用。研究通过分子与细胞水平实验，发现LENT与解旋酶DHX36形成复合体，共同参与核糖体相关翻译调控，维持内质网及线粒体稳态。LENT沉默导致自噬与线粒体功能紊乱，从而诱导细胞凋亡。该研究创新性地将lncRNA与翻译控制和细胞代谢维持机制相联系，但其具体作用谱系及临床转化潜力仍需进一步验证。

---

## 22. 作者更正：针对靶向蛋白降解的CRL2 E3连接酶非抑制性适配体配体的鉴定。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419487)
**期刊：** Nature communications
**PMID：** 41419487
**DOI：** 10.1038/s41467-025-67758-6

### 第一部分 原文与翻译

**英文原标题：** Author Correction: Identification of a non-inhibitory aptameric ligand to CRL2 E3 ligase for targeted protein degradation.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

该文是一篇发表在《Nature Communications》上的作者更正通知，涉及一项关于识别CRL2 E3连接酶非抑制性适配体配体以促进靶向蛋白降解的研究。虽然本文不含摘要，但从标题可推测，研究重点在于通过特异性适配体介导蛋白降解的分子机制探索。此类研究有助于药物发现和靶向降解策略的发展。更正的发布体现了作者对数据与结果准确性的严谨态度。

---

## 23. 在人工智能辅助医疗的社会技术仿真案例研究中连接算法公平性与公正结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419484)
**期刊：** Nature communications
**PMID：** 41419484
**DOI：** 10.1038/s41467-025-67470-5

### 第一部分 原文与翻译

**英文原标题：** Connecting algorithmic fairness and fair outcomes in a sociotechnical simulation case study of AI-assisted healthcare.

> **英文摘要：**
> Artificial intelligence (AI) has vast potential for improving healthcare delivery, but concerns regarding biases in these systems have raised important questions regarding fairness when deployed clinically. Most prior studies on fairness in clinical AI focus solely on performance disparities between subpopulations, which often fall short of connecting the technical outputs of AI systems with sociotechnical outcomes. In this work, we present a simulation-based approach to explore how statistical definitions of algorithmic fairness translate to fairness in long-term outcomes, using AI-assisted breast cancer screening as a case example. We evaluate four fairness criteria and their impact on mortality rates and socioeconomic disparities, while also considering how clinical decision makers' reliance on AI and patients' access to healthcare affect outcomes. Our results highlight how algorithmic fairness does not directly translate into fair and equitable outcomes, underscoring the importance of integrating sociotechnical perspectives to gain a holistic understanding of fairness in healthcare AI.

> **中文摘要：**
> 人工智能（AI）在提升医疗服务方面具有巨大的潜力，但这些系统中潜在的偏倚问题引发了关于其临床应用公平性的重大质疑。以往关于临床AI公平性的研究大多仅关注不同亚群体之间的性能差异，而往往未能将AI系统的技术输出与社会技术层面的结果联系起来。本研究提出了一种基于仿真的方法，旨在探讨算法公平性的统计定义如何转化为长期结果中的公平性，并以AI辅助乳腺癌筛查为案例进行研究。研究评估了四种公平性准则及其对死亡率和社会经济差距的影响，同时考虑了临床决策者对AI的依赖程度以及患者获得医疗服务的机会对结果的作用。研究结果强调，算法公平性并不能直接转化为公平和公正的结果，凸显了将社会技术视角纳入以全面理解医疗AI公平性的重要性。

### 第二部分 AI 大师评价

该研究通过社会技术仿真方法探讨技术层面的算法公平性如何影响真实的临床与社会结果，采用AI辅助乳腺癌筛查为场景，系统评估了不同公平性定义下的死亡率与社会经济差异。研究指出技术公平不等于社会公平，揭示了AI系统在医疗应用中存在的复杂公平性传导机制。该工作创新性地将统计公平指标与社会技术结果相连接，为跨学科公平性评估提供了新框架，同时提示未来研究需进一步探索现实环境中的外部影响因素。

---

## 24. 独特的胃肠道微生物特征可预测恒河猴与人类控制性疟原虫感染中的寄生虫水平

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419476)
**期刊：** Nature communications
**PMID：** 41419476
**DOI：** 10.1038/s41467-025-67241-2

### 第一部分 原文与翻译

**英文原标题：** Distinct gastrointestinal microbial signatures predict parasite levels in controlled Plasmodium infections in both rhesus macaques and humans.

> **英文摘要：**
> Functions of the gastrointestinal (GI) microbiome include maintenance of immune homeostasis and protection against infectious disease. Current assessments of the role of the GI microbiome in Plasmodium infection have been primarily conducted using mouse models and observational human cohorts. Here, we experimentally assessed associations between pre-infection GI microbiome composition and acute Plasmodium parasitemia using 16S rRNA sequencing and samples from rhesus macaques (RMs) and adult humans enrolled in a previously conducted controlled human malaria infection (CHMI) trial (NCT04072302) originally designed to test the efficacy of KAF156, a novel imidazolopiperazine class of antimalarial drugs. We identified distinct pre-infection 16S microbial signatures that were associated with increased risk for above median parasitemia in RMs infected with P. fragile and CHMI participants infected with P. falciparum. Further, we identified a Bifidobacterium feature set that accurately stratified parasitemia risk and could therefore serve as a foundation for a potential biomarker panel to aid prevention efforts in malaria endemic regions. Together, our findings demonstrate that pre-infection GI microbiome composition is indicative of risk for Plasmodium parasitemia, and our observation that the pre-infection microbiome-P. fragile dynamic in RMs mirrors the pre-infection microbiome-P. falciparum interaction in CHMI participants supports the future use of this model in pre-clinical investigations of novel microbiome-targeting approaches to reduce malaria burden.

> **中文摘要：**
> 胃肠道（GI）微生物群的功能包括维持免疫稳态和抵御传染病。目前对GI微生物群在疟原虫感染中作用的评估主要基于小鼠模型和人群观察性研究。在本研究中，我们通过16S rRNA测序，使用恒河猴（RMs）和参加先前开展的受控人类疟疾感染（CHMI）试验（NCT04072302）的成年人体样本，实验性评估了感染前GI微生物群组成与急性疟原虫血症之间的关联。该CHMI试验最初旨在测试一种新型咪唑哌嗪类抗疟药物KAF156的疗效。我们发现，感染前存在不同的16S微生物特征，与感染P. fragile的恒河猴和感染P. falciparum的CHMI受试者中高于中位数的寄生虫血症风险升高相关。此外，我们鉴定出一组双歧杆菌特征，可准确地分层寄生虫血症风险，因此可能作为潜在生物标志物面板的基础，用于疟疾流行地区的防控工作。总体而言，我们的研究结果表明，感染前GI微生物群的组成可指示疟原虫血症的风险；同时，我们发现，恒河猴中感染前微生物群—P. fragile的动态模式与CHMI受试者中感染前微生物群—P. falciparum的相互作用相似，支持在未来临床前研究中使用该模型以探索针对微生物群的新型疟疾减负策略。

### 第二部分 AI 大师评价

该研究通过跨物种比较，揭示了胃肠道微生物群在调控疟原虫感染风险中的关键作用。研究利用恒河猴模型与受控人类疟疾感染试验，结合16S rRNA测序精确解析感染前微生物组特征与寄生虫血症程度之间的关联。尤其是双歧杆菌群的特征集合表现出良好的风险分层预测能力，提示其具有潜在的生物标志物价值。研究创新性在于提供了感染前微生物群组成预测疟疾风险的实验证据，但样本规模及因果推断仍需进一步研究验证。

---

## 25. 促血小板生成素增加EVI1 + KMT2A-MLLT3驱动、表达与不良预后相关干细胞基因的急性髓系白血病的易感性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419472)
**期刊：** Nature communications
**PMID：** 41419472
**DOI：** 10.1038/s41467-025-67611-w

### 第一部分 原文与翻译

**英文原标题：** Thrombopoietin increases susceptibility for EVI1 + KMT2A-MLLT3-driven AML expressing stem cell genes linked to poor outcome.

> **英文摘要：**
> To address the cellular origin of ecotropic virus integration site 1 (EVI1)-expressing aggressive KMT2A-rearranged acute myeloid leukaemia (AML) we integrate an Evi1-GFP reporter allele in the inducible iKMT2A-MLLT3 mouse model. We observe that a single injection of thrombopoietin (TPO) selectively increases the number of cycling Evi1 haematopoietic stem cells (HSC) and accelerates AML initiation. Comparison of mouse Evi1 KMT2-MLLT3 AML originating from TPO-stimulated HSC with human EVI1AML reveals higher expression of HSC genes including IL12Rβ2 and INPP4B linked to poor disease outcome of patients of four large AML cohorts. Knockdown experiments show exclusive MECOM-dependency of human EVI1 KMT2A-rearranged OCI-AML4 cells while reduction of IL12Rβ2 also impairs clonogenic growth of EVI1 MOLM-13, THP-1 or HL-60 AML cells. Collectively, we show that exogenous factors like TPO can increase the susceptibility for iKMT2A-MLLT3-driven HSC-originating Evi1 AML expressing stem cell genes linked to transformation maintenance of cell lines, and poor disease outcome of patients.

> **中文摘要：**
> 为探究表达生态型病毒整合位点1（EVI1）的高侵袭性KMT2A重排急性髓系白血病（AML）的细胞起源，我们在可诱导的iKMT2A-MLLT3小鼠模型中整合了Evi1-GFP报告等位基因。我们观察到，单次注射促血小板生成素（TPO）可选择性地增加处于细胞周期中的Evi1造血干细胞（HSC）数量，并加速AML的起始。将源自TPO刺激的HSC的鼠源Evi1 KMT2-MLLT3 AML与人源EVI1 AML进行比较，发现包括IL12Rβ2和INPP4B在内的HSC相关基因表达水平更高，而这些基因与四个大型AML队列中患者的不良疾病结局相关。基因敲低实验显示，人源EVI1 KMT2A重排的OCI-AML4细胞对MECOM具有特异依赖性，而降低IL12Rβ2的表达也会损害EVI1阳性的MOLM-13、THP-1或HL-60 AML细胞的克隆增殖能力。总体而言，我们的结果表明，TPO等外源性因素可增强iKMT2A-MLLT3驱动的、源自HSC的Evi1 AML的易感性，并促进表达与细胞转化维持及患者不良预后相关的干细胞基因。

### 第二部分 AI 大师评价

本研究旨在探讨表达EVI1的KMT2A重排急性髓系白血病的细胞起源及其外界调控因素。研究者通过建立带有Evi1-GFP报告基因的iKMT2A-MLLT3小鼠模型，发现促血小板生成素可选择性扩增Evi1阳性造血干细胞并加速白血病形成。人鼠模型的比较进一步揭示，TPO诱导的AML具有更高干细胞基因表达，与不良预后密切相关。该研究创新地指出了外源性造血调控因子在AML易感性中的作用机制，为理解白血病起源及潜在治疗靶点提供了新视角，但其在临床背景下的可转化性仍需进一步验证。

---

## 26. 由ADP-核糖环化酶赋能的外泌体化学工程多功能平台

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419470)
**期刊：** Nature communications
**PMID：** 41419470
**DOI：** 10.1038/s41467-025-67661-0

### 第一部分 原文与翻译

**英文原标题：** A versatile platform for chemical engineering of exosomes empowered by ADP-ribosyl cyclases.

> **英文摘要：**
> Cell-secreted exosomes have been emerging as an increasingly attractive form of nanomaterials for biomedical research. Various approaches have been established to genetically modify exosomes with proteins of interest for new and/or improved functions. However, equipping exosomes with diverse non-protein biomolecules remains largely dependent on random chemical conjugation or membrane insertion, hindering the application potential of exosomes. Herein, we develop a technology for site-specific functionalization of exosome with different synthetic groups by exploiting surface-expressed CD38, an ADP-ribosyl cyclase, and its covalent inhibitor derived from nicotinamide adenine dinucleotide (NAD). The designed ADP-ribosyl cyclase-enabled exosomes (ARC Exos) carrying conjugated fluorescent imaging probes, small-molecule ligands, cytotoxic payloads, and bone-targeting agents are demonstrated with in vitro and/or in vivo activities and specificities. This ARC Exos-based platform provides a general approach with great versatility for chemically reprogramming exosomes.

> **中文摘要：**
> 细胞分泌的外泌体正逐渐成为生物医学研究中极具吸引力的一种纳米材料形式。已经建立了多种方法，可通过基因工程将目标蛋白修饰到外泌体中，以获得新的和/或增强的功能。然而，将多样的非蛋白类生物分子装载到外泌体上仍主要依赖随机的化学偶联或膜插入方式，从而限制了外泌体的应用潜力。在本研究中，我们建立了一种技术，通过利用膜表面表达的ADP-核糖环化酶CD38及其来源于烟酰胺腺嘌呤二核苷酸（NAD）的共价抑制剂，实现外泌体的位点特异性修饰，使其携带不同的合成官能团。设计得到的ADP-核糖环化酶赋能外泌体（ARC Exos）可共价结合荧光成像探针、小分子配体、细胞毒性载荷及骨靶向剂，并在体内外实验中展示了特定的活性与特异性。基于ARC Exos的平台为外泌体的化学重编程提供了一种通用且高度灵活的途径。

### 第二部分 AI 大师评价

该研究旨在通过ADP-核糖环化酶介导的化学修饰技术，构建一种能实现外泌体位点特异性功能化的通用平台。研究团队利用CD38及其NAD衍生抑制剂，实现了多种合成基团在外泌体表面的可控加载，扩大了外泌体在成像、药物递送和靶向治疗等领域的应用潜能。实验验证表明，该技术不仅提升了外泌体的多功能化水平，还保持了其生物活性。该平台的创新在于实现了化学与生物修饰策略的结合，但未来仍需进一步验证其大规模生产与体内长期安全性。

---

## 27. PRDM1驱动的SLC30A9高表达通过促进线粒体过度功能促进宫颈癌细胞的恶性表型。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419464)
**期刊：** Cell death & disease
**PMID：** 41419464
**DOI：** 10.1038/s41419-025-08264-x

### 第一部分 原文与翻译

**英文原标题：** PRDM1-driven SLC30A9 overexpression contributes to the malignant phenotype of cervical cancer cells via promoting mitochondrial hyperfunction.

> **英文摘要：**
> Mitochondrial hyperfunction is important for cervical cancer progression. Solute carrier family 30 member 9 (SLC30A9) is a member of the solute carrier family 30, specifically a zinc transporter that plays a critical role in mitochondrial zinc homeostasis and maintaining mitochondrial function. We investigated the expression, function, and underlying mechanisms of SLC30A9 in the context of cervical cancer. Single-cell RNA sequencing analysis revealed a marked overexpression of SLC30A9 within the malignant epithelial cell population of cervical squamous cell carcinoma. This elevated SLC30A9 expression was further corroborated in clinical specimens from local patients and across various established and primary cervical cancer cells. SLC30A9 shRNA or knockout (via CRISPR/Cas9 method) significantly impeded the viability, proliferation, cell cycle progression and migration, and triggered apoptosis in cervical cancer cells. SLC30A9 depletion disrupted mitochondrial function, inhibiting mitochondrial respiration, mitochondrial membrane potential, mitochondrial complex I activity, and ATP production, also caused mitochondrial Zn accumulation, reactive oxygen species (ROS) production and oxidative injury. Conversely, overexpression of SLC30A9 in cervical cancer cells demonstrated enhanced mitochondrial complex I activity, increased ATP production, and augmented cellular proliferation and migration. Bioinformatic analysis, coupled with functional validation, identified PRDM1 (PR Domain Containing 1) as a key transcription factor regulating SLC30A9 expression. Silencing or knockout of PRDM1 resulted in a significant reduction in SLC30A9 promoter activity, as well as decreased SLC30A9 mRNA and protein levels in primary cervical cancer cells. Chromatin immunoprecipitation (ChIP) assays confirmed increased PRDM1 binding to the SLC30A9 promoter region in cervical cancer tissues. In vivo studies showed that SLC30A9 knockdown led to a remarkable decrease in the growth of xenografts formed by primary cervical cancer cells. These SLC30A9-silenced xenografts exhibited mitochondrial dysfunction, proliferation inhibition and apoptosis induction. These findings collectively suggest that PRDM1-driven SLC30A9 overexpression significantly contributes to the malignant phenotype of cervical cancer, possibly through promoting mitochondrial hyperfunction.

> **中文摘要：**
> 线粒体的过度功能对宫颈癌的进展具有重要作用。溶质载体家族30的成员9（SLC30A9）属于溶质载体家族30，是一种锌转运蛋白，在维持线粒体锌稳态和线粒体功能中起关键作用。我们在宫颈癌的背景下研究了SLC30A9的表达、功能及其潜在机制。单细胞RNA测序分析显示，在宫颈鳞状细胞癌的恶性上皮细胞群中，SLC30A9呈显著过表达。进一步研究发现，这种高水平的SLC30A9表达同样在本地患者的临床标本以及多种建立的和原代宫颈癌细胞中得到验证。通过shRNA或CRISPR/Cas9方法敲低或敲除SLC30A9显著抑制了宫颈癌细胞的活性、增殖、细胞周期进程和迁移，并诱导了细胞凋亡。SLC30A9缺失导致线粒体功能受损，抑制了线粒体呼吸、线粒体膜电位、线粒体复合物I活性及ATP生成，同时引起线粒体内Zn积累、活性氧（ROS）生成及氧化损伤。相反，在宫颈癌细胞中过表达SLC30A9可增强线粒体复合物I活性，提高ATP生成，并促进细胞增殖和迁移。生物信息学分析结合功能学验证发现PRDM1（含PR结构域的蛋白1）是调控SLC30A9表达的重要转录因子。沉默或敲除PRDM1显著降低SLC30A9启动子活性，并减少原代宫颈癌细胞中SLC30A9的mRNA和蛋白水平。染色质免疫沉淀（ChIP）实验验证了PRDM1在宫颈癌组织中对SLC30A9启动子区域的结合增强。体内研究表明，SLC30A9敲低显著抑制了由原代宫颈癌细胞形成的异种移植瘤的生长。这些SLC30A9沉默的异种移植瘤表现出线粒体功能障碍、增殖受抑以及凋亡诱导。综合这些结果表明，PRDM1驱动的SLC30A9过度表达显著促进了宫颈癌的恶性表型，其机制可能与促进线粒体过度功能相关。

### 第二部分 AI 大师评价

该研究揭示了转录因子PRDM1通过上调SLC30A9促进宫颈癌发生发展的分子机制。作者运用单细胞测序、功能干预及体内实验，系统阐明SLC30A9在维持线粒体功能和细胞恶性表型中的关键作用。研究创新性地提出“线粒体过度功能”在肿瘤恶性进展中的驱动地位，并建立了PRDM1–SLC30A9调控轴，为宫颈癌的代谢靶向治疗提供了新的理论依据。然而，该研究仍需进一步探索其在临床人群中的预后相关性及潜在治疗干预价值。

---

## 28. 一种由超级增强子驱动的新型长链非编码RNA LINC00973通过EN2调控头颈部鳞状细胞癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419462)
**期刊：** Cell death & disease
**PMID：** 41419462
**DOI：** 10.1038/s41419-025-08380-8

### 第一部分 原文与翻译

**英文原标题：** A novel super-enhancer-driven lncRNA LINC00973 governs head and neck squamous cell carcinoma progression through EN2.

> **英文摘要：**
> Long noncoding RNAs (lncRNAs) have emerged as pivotal regulators driving cancer development and potential therapeutic targets across multiple human malignancies. However, their mechanistic roles during head and neck squamous cell carcinoma (HNSCC) initiation and progression remain incompletely elucidated. Here, we identified a novel oncogenic lncRNA, LINC00973, which was aberrantly upregulated in clinical samples and associated with aggressive clinicopathological features and adverse clinical outcomes. LINC00973 promoted cell proliferation, migration, and invasion and inhibited cell apoptosis and senescence in vitro, and induced tumor growth and lymph node metastasis in vivo. Mechanistically, LINC00973 functioned as a molecular sponge for tumor-suppressive miR-6756-3p, consequently stabilizing transcription factor Engrailed-2 (EN2) mRNA and activating NOTCH pathway to promote HNSCC progression. Integrative epigenomics/transcriptomics analyses coupled with molecular assays revealed a proximal super-enhancer (SE) within the LINC00973 locus, which recruited Activator Protein 1 (AP-1)/FOS Like 1 (FOSL1), BRD4, and EP300, thereby collectively activating its transcription. CRISPR interference assay identified four functional enhancer elements of LINC00973-SE and H3K27ac HiChIP data analysis suggested enhancer-promoter contacts, collectively contributing to LINC00973 transcription. Clinically, the abundance of LINC00973, miR-6756-3p, EN2, and NOTCH1 in HNSCC samples was correlated and significantly associated with patients' survival. Collectively, our findings revealed a hitherto uncharacterized SE-driven LINC00973-miR-6756-3p-EN2 regulatory axis to facilitate HNSCC progression and highlighted LINC00973 as a promising prognostic biomarker and therapeutic target with considerable translational potential.

> **中文摘要：**
> 长链非编码RNA（lncRNA）已被认为是驱动癌症发生发展的关键调控因子，并在多种人类恶性肿瘤中作为潜在治疗靶点。然而，它们在头颈部鳞状细胞癌（HNSCC）发生和进展过程中的分子机制尚未被充分阐明。在本研究中，我们鉴定出一种新的致癌性lncRNA——LINC00973，它在临床样本中异常高表达，并与侵袭性临床病理特征及不良预后密切相关。LINC00973在体外促进细胞增殖、迁移和侵袭，并抑制细胞凋亡与衰老；在体内可诱导肿瘤生长和淋巴结转移。从机制上看，LINC00973作为肿瘤抑制性miR-6756-3p的分子海绵，进而稳定转录因子Engrailed-2（EN2）的mRNA，激活NOTCH信号通路，从而促进HNSCC进展。整合的表观基因组学与转录组学分析结合分子实验揭示，在LINC00973基因座中存在一个近端超级增强子（SE），该区域可招募激活蛋白1（AP-1）/FOS样蛋白1（FOSL1）、BRD4和EP300，从而协同激活其转录。CRISPR干扰实验鉴定出了LINC00973-SE的四个功能性增强子元件，并且H3K27ac HiChIP数据分析提示增强子与启动子间的接触，共同促进LINC00973的转录。临床上，HNSCC样本中LINC00973、miR-6756-3p、EN2和NOTCH1的表达水平相互相关，并与患者生存显著相关。综上所述，我们的研究揭示了一个此前未被描述的由超级增强子驱动的LINC00973–miR-6756-3p–EN2调控轴，促进HNSCC进展，并强调了LINC00973作为预后生物标志物和治疗靶点的潜在转化价值。

### 第二部分 AI 大师评价

本研究系统揭示了超级增强子驱动的lncRNA LINC00973在头颈部鳞状细胞癌中的作用机制。研究者通过多组学分析结合体内外功能实验，发现LINC00973通过吸附miR-6756-3p稳定EN2并激活NOTCH通路，促进肿瘤进展。该研究从表观调控层面构建了LINC00973–miR–EN2的信号轴，拓展了对HNSCC分子驱动机制的理解。其创新性在于发现了LINC00973的超级增强子调控机制，而潜在局限在于临床样本量及对其他肿瘤类型的验证仍需进一步研究。

---

## 29. EBV相关胃癌中EBNA1-YAP信号轴通过CD276介导免疫逃逸

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419460)
**期刊：** Cell death & disease
**PMID：** 41419460
**DOI：** 10.1038/s41419-025-08251-2

### 第一部分 原文与翻译

**英文原标题：** An EBNA1-YAP signaling axis drives immune escape through CD276 in EBV-associated gastric cancer.

> **英文摘要：**
> Clinical efficacy of anti-PD1 immunotherapy often yields low response rates in Epstein-Barr virus-associated gastric cancer (EBVaGC). To gain insights into immune escape mechanisms and discover critical molecules in anti-tumor immunity, we performed an immune checkpoint screening using transcriptome profiling and immunohistochemistry analyses. We identified CD276 as an independent immunosuppressive molecule that correlates with poor EBVaGC prognosis. Our in vitro and in vivo experiments demonstrate the role of CD276 in inducing T cell apoptosis and diminishing chemokine secretion, thereby dampening immune response and facilitating tumor progression. Mechanistically, we discovered that YAP/TEAD4 chromatin occupancy at CD276 regulatory regions leads to its transcriptional upregulation in EBVaGC, driven by EBNA1-stimulated MST1/2-LATS1/2-YAP signaling. Notably, in a humanized xenograft mouse model, EBVaGC with elevated CD276 levels exhibited resistance to anti-PD1 immunotherapy, while targeting CD276 in combination with PD1 blockade significantly reduced tumor size. Collectively, our findings elucidate the EBNA1-YAP-CD276 axis as a novel mechanism of immune escape in EBVaGC, providing insights for enhanced immunotherapeutic strategies.

> **中文摘要：**
> 抗PD1免疫治疗在EB病毒相关胃癌（EBVaGC）中的临床疗效常表现为低应答率。为深入了解免疫逃逸机制并发现抗肿瘤免疫中的关键分子，我们通过转录组分析和免疫组织化学检测进行了免疫检查点筛选。我们鉴定出CD276是一种独立的免疫抑制分子，其表达与EBVaGC的不良预后相关。我们的体内外实验表明，CD276可诱导T细胞凋亡并减少趋化因子分泌，从而削弱免疫反应并促进肿瘤进展。在机制上，我们发现YAP/TEAD4在CD276调控区域的染色质结合可促进其在EBVaGC中的转录上调，该过程由EBNA1激活的MST1/2-LATS1/2-YAP信号通路驱动。值得注意的是，在人源化异种移植小鼠模型中，高表达CD276的EBVaGC对抗PD1免疫治疗表现出耐药性，而在PD1阻断基础上联合靶向CD276可显著减小肿瘤体积。综上，我们的研究揭示了EBNA1-YAP-CD276信号轴作为EBVaGC免疫逃逸的新机制，为优化免疫治疗策略提供了新的思路。

### 第二部分 AI 大师评价

本研究旨在揭示EB病毒相关胃癌中免疫逃逸的分子机制。通过结合转录组分析、免疫组化及动物模型，作者系统阐明了EBNA1激活的YAP信号通路如何通过上调CD276导致免疫抑制。研究发现CD276不仅诱导T细胞凋亡，还与抗PD1治疗耐受相关，提示其作为免疫治疗靶点的潜力。该研究在机制解析和治疗策略拓展方面具有创新性，但仍需进一步验证该通路在人类临床样本及多重免疫环境中的普适性。

---

## 30. CAMK1D 通过激活 AMPK/PINK1/Parkin 依赖性线粒体自噬促进前列腺癌的恩杂鲁胺耐药性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419457)
**期刊：** Cell death & disease
**PMID：** 41419457
**DOI：** 10.1038/s41419-025-08342-0

### 第一部分 原文与翻译

**英文原标题：** CAMK1D activates AMPK/PINK1/Parkin-dependent mitophagy to promote enzalutamide resistance in prostate cancer.

> **英文摘要：**
> Although androgen receptor (AR)-targeted therapies, such as enzalutamide, initially improve outcomes of prostate cancer (PCa) patients, resistance inevitably develops, partly driven by prostate cancer stem-like cells (PCSCs). However, the molecular mechanisms linking the maintenance of PCSCs to enzalutamide resistance (ENZR) remain incompletely elucidated. Here, we implicate Ca²⁺/calmodulin-dependent protein kinase 1D (CAMK1D) in PCSC-mediated ENZR. CAMK1D was consistently upregulated in PCa with ENZR and contributed to ENZR by enhancing mitophagy in PCa cells both in vitro and in vivo. Mechanistically, CAMK1D promotes the expansion of PCSCs by enhancing mitophagy through activation of the AMP-activated protein kinase (AMPK)/PINK1 signaling pathway, thereby facilitating cellular adaptation. We revealed that CAMK1D interacts with and phosphorylates AMPK at Thr172, which in turn activates PINK1 to modulate mitophagy, ultimately supporting the expansion of PCSCs under enzalutamide treatment. In a mouse orthotopic PCa model, targeting the CAMK1D/AMPK pathway with the siCAM/HLNP nanoformulation suppresses tumor growth by depleting the PCSCs population, achieving a synergistic effect with enzalutamide therapy. Our findings identify CAMK1D as a key regulator of ENZR that maintains stemness by orchestrating mitophagy, thereby establishing mitophagy as an important nexus between CAMK1D-mediated ENZR and AMPK-driven PCSC enrichment. Therapeutically, we developed a CAMK1D-targeted approach that potently reverses ENZR and improves treatment responses.

> **中文摘要：**
> 尽管雄激素受体（AR）靶向治疗（如恩杂鲁胺）最初可改善前列腺癌（PCa）患者的治疗效果，但耐药性最终不可避免地发生，这在一定程度上由前列腺癌干样细胞（PCSCs）驱动。然而，将 PCSCs 维持与恩杂鲁胺耐药（ENZR）联系起来的分子机制尚未完全阐明。在本研究中，我们证明了 Ca²⁺/钙调蛋白依赖性蛋白激酶 1D（CAMK1D）参与了由 PCSC 介导的 ENZR。研究发现，CAMK1D 在具有 ENZR 的 PCa 中持续上调，通过增强体内外 PCa 细胞的线粒体自噬促进耐药形成。在机制上，CAMK1D 通过激活 AMP 激活蛋白激酶（AMPK）/PINK1 信号通路增强线粒体自噬，从而促进 PCSCs 的扩增并有利于细胞适应。我们揭示，CAMK1D 与 AMPK 相互作用并在 Thr172 位点磷酸化 AMPK，进而激活 PINK1 调控线粒体自噬，最终在恩杂鲁胺处理下支持 PCSCs 的扩增。在小鼠前列腺癌原位模型中，采用 siCAM/HLNP 纳米制剂靶向 CAMK1D/AMPK 通路，通过耗竭 PCSCs 群体抑制肿瘤生长，并与恩杂鲁胺治疗产生协同效应。我们的研究结果确定了 CAMK1D 是维持干性并调控线粒体自噬的 ENZR 关键调节因子，从而确立了线粒体自噬作为连接 CAMK1D 介导的 ENZR 与 AMPK 驱动的 PCSC 增殖之间的重要枢纽。在治疗上，我们开发了一种靶向 CAMK1D 的方法，可有效逆转 ENZR 并改善治疗反应。

### 第二部分 AI 大师评价

本研究揭示 CAMK1D 在前列腺癌恩杂鲁胺耐药中的关键作用，通过激活 AMPK/PINK1 依赖的线粒体自噬维持干样细胞扩增。作者结合体内外实验及小鼠模型，系统阐明了 CAMK1D-AMPK-PINK1 轴在耐药性形成中的分子链条。创新之处在于首次将线粒体自噬确立为连接干性维持与药物耐受的重要枢纽，并提出纳米制剂干预策略。该研究为克服雄激素受体靶向治疗耐药提供了新思路，但仍需进一步临床验证其安全性与转化潜力。

---

## 31. USP11通过稳定EGFR和TRAF6促进结直肠癌进展：一种在EGFR和TLR驱动肿瘤发生中的潜在治疗靶点

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419456)
**期刊：** Cell death & disease
**PMID：** 41419456
**DOI：** 10.1038/s41419-025-08266-9

### 第一部分 原文与翻译

**英文原标题：** USP11 promotes colorectal cancer progression by stabilizing EGFR and TRAF6: a potential therapeutic target in EGFR- and TLR-driven tumorigenesis.

> **英文摘要：**
> Ubiquitin-specific proteases (USPs) are key regulators of protein homeostasis and have been implicated in various aspects of cancer development, including colorectal cancer (CRC). In this study, we investigated the role of USP11 in CRC pathogenesis. RNA-seq analysis of tumor and matched normal tissues from 35 CRC patients identified USP11 as significantly overexpressed in tumor samples. Elevated USP11 expression was correlated with reduced patient survival, suggesting its prognostic significance. Functional experiments using USP11-knockout and USP11-overexpressing CRC cell lines (HCT-15 and HT-29) revealed that USP11 promotes tumor cell proliferation, migration, colony formation, and 3D spheroid growth. Biochemical assays demonstrated that USP11 stabilizes EGFR and TRAF6 by removing K48-linked ubiquitin chains, thereby preventing their proteasomal degradation. These interactions potentiate both EGFR and Toll-like receptor (TLR) signaling pathways, contributing to CRC tumorigenesis. Loss of USP11 led to significant reductions in EGFR and TRAF6 protein levels, resulting in impaired tumorigenic behavior in vitro and in mouse xenograft models. Furthermore, USP11 deficiency suppressed tumor spheroid formation in response to EGF, HKLM (a TLR2 agonist), and LPS (a TLR4 agonist), whereas USP11 overexpression amplified these effects. Importantly, pharmacological inhibition of USP11 with mitoxantrone markedly decreased spheroid growth in both EGFR- and TLR-driven models, supporting its therapeutic potential. Overall, our findings reveal that USP11 contributes to CRC progression by stabilizing EGFR and TRAF6, thereby enhancing oncogenic signaling. These insights identify USP11 as a promising molecular target for CRC treatment and support the repurposing of mitoxantrone as an inhibitor of USP11-driven tumor growth.

> **中文摘要：**
> 泛素特异性蛋白酶（USPs）是蛋白质稳态的重要调控因子，已被证明参与包括结直肠癌（CRC）在内的多种癌症发展过程。在本研究中，我们探讨了USP11在CRC发病机制中的作用。对35例CRC患者的肿瘤组织及配对正常组织进行的RNA测序分析显示，USP11在肿瘤样本中显著高表达。USP11表达升高与患者生存率降低相关，提示其具有预后意义。采用USP11敲除和USP11过表达的CRC细胞系（HCT-15和HT-29）的功能实验表明，USP11促进肿瘤细胞的增殖、迁移、克隆形成及三维类球体生长。生化分析显示，USP11通过去除K48连接的泛素链稳定EGFR和TRAF6，从而防止其经蛋白酶体降解。这些相互作用增强了EGFR和Toll样受体（TLR）信号通路，促进了CRC的肿瘤发生。USP11缺失导致EGFR和TRAF6蛋白水平显著下降，从而在体外以及小鼠异种移植模型中削弱了肿瘤形成能力。此外，USP11缺乏抑制了细胞在EGF、HKLM（TLR2激动剂）和LPS（TLR4激动剂）刺激下的类球体形成，而USP11过表达则增强了这些效应。重要的是，使用米托蒽醌药理抑制USP11可显著降低EGFR和TLR驱动模型中的类球体生长，支持其作为潜在治疗靶点的可行性。总体而言，我们的研究揭示USP11通过稳定EGFR和TRAF6促进CRC进展，从而增强致癌信号传导。这些发现提示USP11是CRC治疗的有前景分子靶点，并支持米托蒽醌作为USP11驱动肿瘤生长抑制剂的再利用。

### 第二部分 AI 大师评价

该研究系统解析了脱泛素酶USP11在结直肠癌进展中的功能机制，证实其通过稳定EGFR和TRAF6增强EGFR及TLR信号通路，促进肿瘤生长。作者利用多组学分析、细胞功能实验及动物模型，建立了从分子机制到药物干预的完整证据链。研究的重要创新在于提出USP11作为兼具预后与治疗潜力的双重靶点，并发现米托蒽醌可作为其抑制剂具有再利用价值。局限性在于临床验证尚需更多患者样本及机制深度研究。

---

## 32. 缺氧肿瘤外泌体通过 NDUFV2 抑制巨噬细胞炎症和铁死亡，从而增强旁观者肿瘤的放射抗性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419454)
**期刊：** Cell death & disease
**PMID：** 41419454
**DOI：** 10.1038/s41419-025-08357-7

### 第一部分 原文与翻译

**英文原标题：** Hypoxic tumor exosomes suppress macrophage inflammation and ferroptosis via NDUFV2 to enhance bystander tumor radioresistance.

> **英文摘要：**
> Hypoxia-induced radioresistance presents a major barrier to effective radiotherapy of non-small cell lung cancer (NSCLC), while the underlying role of macrophages remaining elusive. In this study, we found that, compared with normoxia-derived tumor exosomes, hypoxia-derived tumor exosomes more potently promoted M2 polarization of macrophages and TGF-β1/IL-10 secretion via NADH: ubiquinone oxidoreductase core subunit V2 (NDUFV2), as evidenced by the increased mitochondrial functions, including oxidative phosphorylation, ATP levels and mitochondrial membrane potentials, which collectively suppressed macrophage ferroptosis in an NDUFV2-dependent manner. When co-cultured with these exosome-educated macrophages, bystander normoxic NSCLC cells acquired radioresistance, which was attributed to the inhibition of ferroptosis. Notably, NDUFV2-knockdown macrophages abrogated this exosome-induced radioresistance. Mechanistically, IL-10 might be a pivotal signaling messenger rendering radioresistance of bystander normoxic cells. In vivo, hypoxic exosomes also conferred radioresistance to NSCLC xenografts in mice with intact macrophage populations but not in those with macrophage depletion. Immunohistochemical analysis revealed that irradiated xenografts treated with hypoxic exosomes exhibited significantly higher expression levels of GPX4, Ki67, HIF1α, CD163, and NDUFV2. Furthermore, GPX4 knockdown in xenografts reversed the radioresistance induced by hypoxic exosomes and was associated with reduced infiltration of M2-polarized macrophages, supporting the central role of ferroptosis in macrophage-regulated, hypoxia-induced radioresistance. Clinical tissue microarray analysis further confirmed that NDUFV2 was significantly upregulated in NSCLC tissues and correlated with advanced stages. Collectively, this study disclosed for the first time that hypoxic exosomes suppressed macrophage inflammatory responses and ferroptosis via NDUFV2, thereby enhancing radioresistance in bystander normoxic NSCLC cells.

> **中文摘要：**
> 缺氧诱导的放射抗性是非小细胞肺癌（NSCLC）放射治疗效果的一大障碍，而巨噬细胞在此过程中的作用尚不明确。本研究发现，与常氧来源的肿瘤外泌体相比，缺氧肿瘤来源的外泌体通过 NADH:泛醌氧化还原酶核心亚基 V2（NDUFV2）更强地促进了巨噬细胞的 M2 极化及 TGF-β1/IL-10 的分泌，这表现为线粒体功能的增强，包括氧化磷酸化、ATP 水平及线粒体膜电位的升高，并共同以依赖 NDUFV2 的方式抑制了巨噬细胞的铁死亡。当这些外泌体教育的巨噬细胞与常氧 NSCLC 细胞共培养时，后者获得了放射抗性，这归因于铁死亡的抑制。值得注意的是，NDUFV2 敲低的巨噬细胞可消除这种外泌体诱导的放射抗性。机制上，IL-10 可能是赋予旁观常氧细胞放射抗性的关键信号分子。体内实验表明，在巨噬细胞完整的小鼠中，缺氧外泌体同样赋予 NSCLC 异种移植瘤放射抗性，而在巨噬细胞耗竭小鼠中则无此效应。免疫组化分析显示，接受缺氧外泌体处理并接受辐射的异种移植瘤中，GPX4、Ki67、HIF1α、CD163 及 NDUFV2 的表达水平显著升高。此外，在异种移植瘤中敲低 GPX4 可逆转缺氧外泌体诱导的放射抗性，并伴随 M2 型巨噬细胞浸润的减少，进一步支持了铁死亡在巨噬细胞调控的缺氧诱导放射抗性中的核心作用。临床组织芯片分析进一步证实，NDUFV2 在 NSCLC 组织中显著上调，并与肿瘤晚期密切相关。综上所述，本研究首次揭示了缺氧外泌体通过 NDUFV2 抑制巨噬细胞炎症反应和铁死亡，从而增强旁观常氧 NSCLC 细胞的放射抗性。

### 第二部分 AI 大师评价

本研究聚焦于非小细胞肺癌中缺氧微环境导致的放射抗性机制，揭示巨噬细胞在其中的关键调控作用。研究者通过比较缺氧与常氧外泌体的功能，发现 NDUFV2 介导的线粒体活化抑制了巨噬细胞铁死亡，并通过 IL-10 信号增强了肿瘤的放射抗性。体内外实验及临床验证均支持该机制的可靠性，强调铁死亡调控在放疗抗性形成中的作用。该研究创新性地将缺氧外泌体、巨噬细胞代谢及放射抗性联系起来，为改善放疗敏感性提供了潜在靶点，但尚需进一步阐明临床可转化性的可行性与特异性安全性。

---

## 33. 用于恶性胃出口梗阻的内镜下胃空肠吻合术：再次干预的需求具有变异性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419304)
**期刊：** Gut
**PMID：** 41419304
**DOI：** 10.1136/gutjnl-2025-337514

### 第一部分 原文与翻译

**英文原标题：** Endoscopic gastroenterostomy for malignant gastric outlet obstruction: the need for reintervention is variable.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究评估了内镜下胃空肠吻合术（EUS-GE）在治疗恶性胃出口梗阻中的再干预需求差异。尽管摘要未提供详细数据，但标题暗示研究者探讨了该技术在不同患者群体或病变类型中的持久性与并发症管理。其创新性可能在于揭示内镜介入疗法在肿瘤性梗阻中的动态疗效差异。研究结果对于临床制定个体化治疗策略、优化姑息性消化道重建方案具有重要参考价值。

---

## 34. 遗传性慢性胰腺炎诱导的可塑性与突变型Kras协同促进早期胰腺癌发生。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41419303)
**期刊：** Gut
**PMID：** 41419303
**DOI：** 10.1136/gutjnl-2025-335947

### 第一部分 原文与翻译

**英文原标题：** Hereditary chronic pancreatitis induced plasticity cooperates with mutant Kras in early pancreatic carcinogenesis.

> **英文摘要：**
> BACKGROUND: Chronic pancreatitis (CP) is a risk factor for pancreatic cancer, with inherited cases conferring a markedly increased risk. The underlying mechanisms driving malignant transformation by CP remain poorly understood.
> 
> OBJECTIVE: Combining a recently developed mouse model of CP carrying the human carboxypeptidase A1 () p.N256K mutation with the established  pancreatic cancer model, we characterised mechanisms linking chronic inflammation to early pancreatic carcinogenesis.
> 
> DESIGN: We crossed   mice (Cpa1) with  (KC). In Cre, Cpa1, KC and KC-Cpa1 mice, we performed phenotypical characterisation at five early time points and in an ageing cohort. Assessment of histology combined with both RNA-sequencing and single-cell RNA-sequencing was performed to analyse metaplasia, preneoplastic lesions and cellular heterogeneity.
> 
> RESULTS: KC-Cpa1 pancreata displayed a stark increase in remodelling, fibrosis and formation of metaplastic lesions as compared with KC.  induced extensive plasticity in both the acinar and ductal compartment, including an early acinar-to-ductal metaplasia state in acinar cells characterised by an upregulation of endoplasmic reticulum stress markers and an inflammatory ductal phenotype (iDucts). We characterised the complex cell-cell communication networks underlying both pancreatic inflammation and early carcinogenesis, revealing disease-specific signalling between ductal cells, granulocytes and fibroblasts.
> 
> CONCLUSIONS: The humanised KC-Cpa1 mouse model reveals the interplay of inflammation in hereditary CP and carcinogenesis.  -induced plasticity in acinar and ductal cells, inflammation and cell-cell interaction networks cooperate with  in early pancreatic carcinogenesis.

> **中文摘要：**
> 背景：慢性胰腺炎（CP）是胰腺癌的危险因素，其中遗传性病例的风险显著增加。驱动CP导致恶性转化的潜在机制仍不清楚。
> 
> 目的：本研究将一种携带人源羧肽酶A1（Cpa1）p.N256K突变的、近期开发的慢性胰腺炎小鼠模型与已建立的胰腺癌模型相结合，以阐明慢性炎症与早期胰腺癌发生之间的机制联系。
> 
> 设计：我们将Cpa1小鼠与KC小鼠进行杂交。在Cre、Cpa1、KC和KC-Cpa1小鼠中，于五个早期时间点及老龄队列中进行表型特征分析。通过组织学评估联合RNA测序和单细胞RNA测序分析化生、癌前病变和细胞异质性。
> 
> 结果：与KC相比，KC-Cpa1小鼠的胰腺表现出显著增加的重塑、纤维化和化生性病变形成。该突变诱导了腺泡及导管区域的广泛可塑性，包括腺泡细胞早期的腺泡-导管化生状态，其特征为内质网应激标志物的上调及炎症性导管表型（iDucts）的形成。我们描绘了胰腺炎症及早期癌变相关的复杂细胞间通讯网络，揭示了导管细胞、粒细胞与成纤维细胞之间的疾病特异性信号互作。
> 
> 结论：人源化的KC-Cpa1小鼠模型揭示了遗传性CP中的炎症与癌变之间的相互作用。突变诱导的腺泡和导管细胞可塑性、炎症以及细胞间互作网络与Kras突变协同促进早期胰腺癌的发生。

### 第二部分 AI 大师评价

该研究通过建立人源化的KC-Cpa1小鼠模型，创新性地揭示了遗传性慢性胰腺炎在早期胰腺癌发生中的促癌机制。研究利用多时间点的组织学分析及单细胞转录组技术，系统刻画了炎症诱导的腺泡与导管细胞可塑性及细胞间信号互作。结果显示，Cpa1突变引起的细胞可塑性与Kras突变协同促进胰腺早期癌变，为阐明炎症与癌变的联系提供了新模型和新机制。该模型具有重要的生物学意义，但仍需进一步验证其在人类胰腺癌中的对应性。

---

## 35. 高维蛋白分析揭示原发性与转移性胰腺导管腺癌中不同的免疫及间质特征

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41418102)
**期刊：** Cancer research
**PMID：** 41418102
**DOI：** 10.1158/0008-5472.CAN-25-1697

### 第一部分 原文与翻译

**英文原标题：** High-Dimensional Protein Analysis Uncovers Distinct Immunological and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma.

> **英文摘要：**
> Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor type with poor patient outcomes. Most patients present with metastatic disease, which generally has reduced immune infiltration compared to primary tumors. Further work to elucidate the specific cellular features of metastatic PDAC is needed to guide the development of future immunotherapy strategies. Here, we investigated the hypothesis that PDAC tumors harbor distinct immunologic and stromal features depending on their anatomical site. Multiplex immunohistochemistry (mIHC), spatial analysis, and single-cell mass cytometry (CyTOF) uncovered dominant immune and stromal cell populations in tumors derived from 27 primary and 26 liver metastases. Metastatic liver tumors from PDAC patients contained reduced T cell infiltration, fibroblast populations, and collagen accumulation than primary lesions, while CD68+ cells, often co-expressing CCR2, were more abundant. Spatial analyses revealed distinct immune cell communities in primary and metastatic PDAC, whereby CK19+ cells clustered differentially with α-SMA+, CD3+, and CD68+ cells, depending on the tumor site. When comparing tumor-associated regions, the proportion of peritumoral CK19- cells remained consistent, but their composition varied by disease site. CD8+ T cells were significantly less frequent in metastatic tumors, while both CD4+ and CD8+ T cells present in primary tumors expressed more transcription factors (TFs) associated with suppressive properties, including FoxP3 and RORγt. CyTOF revealed that T cells co-expressed multiple inhibitory checkpoint receptors, most notably LAG-3 and PD-1. This report reveals that primary and metastatic tumors from PDAC patients harbor vastly distinct immunologic and stromal features at the protein level.

> **中文摘要：**
> 胰腺导管腺癌（PDAC）是一种侵袭性极强、患者预后极差的肿瘤类型。大多数患者在诊断时已出现转移性疾病，其免疫细胞浸润程度通常低于原发肿瘤。为了指导未来免疫治疗策略的开发，仍需进一步探究转移性PDAC的特异性细胞特征。在本研究中，我们检验了PDAC肿瘤是否根据其解剖部位而具有不同免疫与间质特征的假设。我们采用多重免疫组织化学（mIHC）、空间分析及单细胞质谱流式细胞术（CyTOF）对来自27例原发肿瘤和26例肝转移病灶的样本进行蛋白组水平的解析，识别出主要的免疫与间质细胞群。结果显示，PDAC患者的肝转移瘤相比原发灶具有更少的T细胞浸润、成纤维细胞群及胶原沉积，而CD68+细胞（常伴随CCR2共表达）则更为丰富。空间分析进一步揭示，原发性与转移性PDAC中的免疫细胞群体组织呈现出明显差异，CK19+细胞与α-SMA+、CD3+及CD68+细胞的空间聚集模式因肿瘤部位而异。对比肿瘤相关区域时，周瘤区CK19−细胞的比例保持相对一致，但其成分随疾病部位不同而发生变化。CD8+ T细胞在转移性肿瘤中显著减少，而原发性肿瘤中的CD4+和CD8+ T细胞则表现出更高水平的与免疫抑制功能相关的转录因子（TFs），包括FoxP3和RORγt。CyTOF结果显示，T细胞同时共表达多种抑制性检查点受体，尤以LAG-3和PD-1最为显著。本研究揭示，来源于PDAC患者的原发与转移性肿瘤在蛋白水平上具有截然不同的免疫及间质特征。

### 第二部分 AI 大师评价

本研究通过高维多组学蛋白分析，系统比较了原发性与肝转移性胰腺导管腺癌的免疫及间质特征。研究综合应用mIHC、空间组学与单细胞质谱流式技术，揭示了不同解剖部位肿瘤的免疫浸润模式、细胞群落空间组织及功能差异。发现转移病灶中T细胞与成纤维细胞减少，而CD68+CCR2+细胞富集，并伴随免疫抑制型T细胞特征。该研究为理解PDAC的部位特异性免疫微环境提供了蛋白组层面的证据，提示未来免疫治疗需针对转移性病灶设计更具靶向性的策略。

---

## 36. 肺癌患者中不同的肿瘤‑免疫生态可预测疾病进展并界定治疗反应的临床生物标志物

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41418101)
**期刊：** Cancer research
**PMID：** 41418101
**DOI：** 10.1158/0008-5472.CAN-25-1594

### 第一部分 原文与翻译

**英文原标题：** Distinct Tumor-Immune Ecologies in Lung Cancer Patients Predict Progression and Define a Clinical Biomarker of Therapy Response.

> **英文摘要：**
> Multiplexed imaging of tissues is an approach that holds promise for improving early detection, diagnosis, and treatment of cancer. Here, we investigated multiplexed histological images of paired pre- and on-treatment samples from nine patients with immunotherapy-refractory non-small cell lung cancer (NSCLC) treated with an oral HDAC inhibitor (vorinostat) combined with a PD-1 inhibitor (pembrolizumab). Patient responses comprised of either stable disease (SD) or progressive disease (PD). An extensive multiplexed-image analysis pipeline involving both cell segmentation and quadrats, coupled with spatial statistics, machine learning, and deep learning was built to analyze the spatial and temporal features that predict disease progression and identify potential clinical biomarkers. Distinct spatial immune ecologies existed between SD and PD patients, and tumors from PD patients were already characterized by an immune-suppressive environment prior to treatment. Finally, the learned spatial ecologies predicted disease progression better than PD-L1 status alone, suggesting these ecologies could be used as potential companion biomarkers with PD-L1 in NSCLC. These findings will be investigated in a larger-cohort study generated from an ongoing clinical trial (NCT02638090) that includes a wider range of responses including complete and partial responders. Together, this study developed a computational infrastructure for analyzing multiplex imaging to predict immunotherapy response in NSCLC, which can potentially be generalized to any type of cancer.

> **中文摘要：**
> 组织多重成像是一种有望改进癌症早期检测、诊断和治疗的方法。在本研究中，我们分析了来自九例免疫治疗耐药的非小细胞肺癌（NSCLC）患者的配对治疗前与治疗中样本的多重组织学图像，这些患者接受了口服HDAC抑制剂（伏立诺他）与PD-1抑制剂（帕博利珠单抗）的联合治疗。患者的反应表现为疾病稳定（SD）或疾病进展（PD）。研究团队建立了一条涵盖细胞分割与网格划分的广泛多重图像分析流程，结合空间统计、机器学习与深度学习，以分析可预测疾病进展的空间与时间特征并识别潜在临床生物标志物。结果显示，SD与PD患者之间存在明显不同的空间免疫生态，而PD患者的肿瘤在治疗前即表现出免疫抑制性微环境。最终，所学习得到的空间生态对疾病进展的预测性能优于单独的PD-L1状态，提示这些生态可作为与PD-L1联合使用的潜在伴随生物标志物于NSCLC中应用。这些发现将于一项正在进行的临床试验（NCT02638090）的更大队列研究中进一步验证，该研究涵盖更广泛的反应类型，包括完全缓解与部分缓解者。总的来看，本研究建立了一个用于分析多重成像以预测NSCLC免疫治疗反应的计算基础设施，并具有推广至其他癌种的潜力。

### 第二部分 AI 大师评价

该研究旨在通过多重组织成像和计算分析揭示非小细胞肺癌中肿瘤‑免疫空间生态与疗效反应之间的关系。作者构建了结合空间统计、机器学习与深度学习的分析框架，从配对样本中提取时间‑空间特征，用于预测疾病进展。结果发现免疫抑制性生态是进展性患者的特征，且这一生态指标优于PD‑L1表达预测疗效。该研究在计算方法与生物标志物识别方面具有创新性，但样本量较小，后续仍需更大队列验证。

---

## 37. Cortactin抑制循环肿瘤细胞中mTOR依赖性衰老的发生。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41418100)
**期刊：** Cancer research
**PMID：** 41418100
**DOI：** 10.1158/0008-5472.CAN-25-1175

### 第一部分 原文与翻译

**英文原标题：** Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells.

> **英文摘要：**
> Tumor senescence is a critical mechanism underlying tumor progression and recurrence. A better understanding of how pre-metastatic circulating tumor cells (CTCs) exploit senescence to survive in the blood stream could help reveal vulnerabilities for therapeutic intervention. Using patient-derived melanoma CTC lines and xenograft models, we identified a role for the cytoskeletal regulator cortactin in mTOR/p53-dependent senescence. Cortactin localized to Rab7-positive endosomes and maintained late-endosomal homeostasis. Depletion of cortactin induced aberrant endosomal aggregates with mTOR accumulation and hyperactivation, subsequently leading to p53 activation, G0/G1 arrest, and cellular senescence. This oncogene-induced senescence (OIS) was characterized by induction of the senescence-associated secretory phenotype and β-galactosidase (SA-β-gal), loss of Ki-67 and lamin B1, and elevated mitochondrial reactive oxygen species (mtROS). Notably, a positive feedback loop between p53 and mtROS was essential for maintaining stable senescence in CTCs. Clinically, the proportion of SA-β-gal-positive senescent CTCs was significantly correlated with therapeutic resistance and disease progression in a prospective cohort of melanoma patients. A sequential strategy using cortactin depletion followed by an anti-Bcl-xL senolytic eliminated the persistent CTCs and suppressed blood-borne metastasis. Thus, this study uncovered a unique senescent CTC subpopulation regulated by a cortactin/mTOR/p53/mtROS axis that can be targeted to suppress metastatic progression of melanoma.

> **中文摘要：**
> 肿瘤细胞衰老是肿瘤进展与复发的关键机制之一。深入理解转移前的循环肿瘤细胞（CTCs）如何利用衰老机制在血液循环中生存，有助于揭示可用于治疗干预的脆弱环节。通过使用患者来源的黑色素瘤CTC细胞系和异种移植模型，我们发现细胞骨架调控蛋白cortactin在mTOR/p53依赖性衰老中发挥重要作用。Cortactin定位于Rab7阳性的内体，并维持晚期内体的稳态。Cortactin的耗竭导致异常的内体聚集体形成，伴随mTOR积累与过度激活，进而引发p53激活、G0/G1期阻滞及细胞衰老。这种由癌基因诱导的衰老（OIS）特征包括衰老相关分泌表型（SASP）与β-半乳糖苷酶（SA-β-gal）的诱导，Ki-67与lamin B1的丧失，以及线粒体活性氧（mtROS）的升高。值得注意的是，p53与mtROS之间的正反馈环路对于维持CTCs中稳定的衰老状态至关重要。在临床上，SA-β-gal阳性的衰老CTCs比例与黑色素瘤患者的治疗耐药性及疾病进展显著相关。采用依次进行的cortactin耗竭与抗Bcl-xL衰老细胞溶解策略可消除持续存在的CTCs并抑制血源性转移。因此，本研究揭示了一种由cortactin/mTOR/p53/mtROS轴调控的独特衰老CTC亚群，可作为抑制黑色素瘤转移进展的潜在靶点。

### 第二部分 AI 大师评价

该研究聚焦于循环肿瘤细胞的衰老调控机制，揭示了cortactin通过mTOR/p53信号轴在抑制肿瘤细胞衰老中发挥关键作用。作者利用患者来源模型与异种移植实验，系统阐明cortactin耗竭后引发的内体异常及其导致的mTOR激活和细胞衰老过程。研究提出p53与线粒体ROS之间的正反馈环路对维持CTC稳定衰老至关重要，并在临床上发现衰老CTCs与治疗耐药及疾病进展显著相关。此成果为通过靶向cortactin/mTOR/p53/mtROS轴以清除难治性CTCs、抑制黑色素瘤转移提供了新的治疗思路。

---

## 38. 答复：“重新审视肝细胞癌局部治疗的方法学范式：来自 SURF 研究的启示”与“关于 SURF 试验的方法学与报告缺陷”。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41418085)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41418085
**DOI：** 10.1200/JCO-25-02390

### 第一部分 原文与翻译

**英文原标题：** Reply to: "Revisiting Methodologic Paradigms in Local Therapies for Hepatocellular Carcinoma: Insights From the SURF Study" and "Methodologic and Reporting Gaps in the SURF Trial".

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文为对两篇关于 SURF 研究设计与报告问题的评论信件的学术回应。文章可能重申研究者对原始研究方法学的立场，解释试验设计选择的合理性，并澄清被质疑的分析或报告细节。其主要贡献在于促进肝细胞癌局部治疗研究中的方法学讨论，推动更严谨的临床试验设计与结果透明化。然而，由于缺乏新的数据或实验结果，文章的创新性较为有限，主要价值在于学术交流与研究规范化。

---

## 39. NeoADAURA 研究：我们能忽视客观缓解率吗？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41418083)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41418083
**DOI：** 10.1200/JCO-25-01336

### 第一部分 原文与翻译

**英文原标题：** NeoADAURA: Can We Afford to Overlook Objective Response Rates?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文聚焦于NeoADAURA研究在非小细胞肺癌靶向治疗中的关键指标——客观缓解率的重要性。作者可能探讨了在关注长期生存数据的同时，是否低估了客观缓解率这一中期疗效指标的临床价值。文章旨在引发对临床试验评价体系的再思考，提醒肿瘤学界平衡短期反应与长期预后的关系。由于缺乏摘要，无法确定其研究方法和结论，但从标题来看，该文强调了疗效评价维度的临床敏感度与决策价值。

---

## 40. 回复“NeoADAURA：我们能否忽视客观缓解率？”及“主要病理缓解是否是新辅助试验的最佳替代终点？”

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41418082)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41418082
**DOI：** 10.1200/JCO-25-02551

### 第一部分 原文与翻译

**英文原标题：** Reply to "NeoADAURA: Can We Afford to Overlook Objective Response Rates?" and "Is Major Pathologic Response the Best Surrogate End Point for Neoadjuvant Trials?".

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本篇文章为对两篇关于新辅助治疗试验设计与评价标准的评论性论文的学术回复。尽管缺乏摘要内容，但从标题来看，作者针对NeoADAURA研究提出的问题展开讨论，重点涉及客观缓解率与主要病理缓解在新辅助研究中的价值判断。该类回复有助于促进专家间的思想交流与临床试验评估标准的进一步完善。然而，由于仅为简短回复，缺乏实证数据支持，其结论的普适性仍需在后续研究中验证。

---

## 41. 重新审视肝细胞癌局部治疗的方法学范式：来自 SURF 研究的启示

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41418075)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41418075
**DOI：** 10.1200/JCO-25-01536

### 第一部分 原文与翻译

**英文原标题：** Revisiting Methodologic Paradigms in Local Therapies for Hepatocellular Carcinoma: Insights From the SURF Study.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究旨在从 SURF 研究中重新审视肝细胞癌局部治疗的研究方法学框架，可能探讨不同局部治疗手段（如消融、切除或放疗）的比较策略与评估标准。尽管缺乏摘要信息，但题目显示作者关注临床试验设计、疗效评估及医学证据质量的优化。此类研究对于重新定义肝癌局部治疗的决策依据与研究范式具有重要的理论与实践价值，预期可推动精准化治疗策略的发展。

---

## 42. SURF 试验中的方法学与报告缺陷

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41418074)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41418074
**DOI：** 10.1200/JCO-25-01687

### 第一部分 原文与翻译

**英文原标题：** Methodologic and Reporting Gaps in the SURF Trial.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文献聚焦于对 SURF 临床试验在方法学设计和报告规范方面的不足进行分析。尽管缺乏摘要，但从标题可推测，作者意在揭示试验方法与报告质量可能存在的偏差或遗漏。此类研究有助于提高临床试验报告透明度与可重复性，推动循证医学质量改进。其局限在于缺乏具体实验数据与结果描述，需后续研究进一步阐明。

---

## 43. 机器学习增强的微流控细胞分选研究进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41417905)
**期刊：** Science advances
**PMID：** 41417905
**DOI：** 10.1126/sciadv.aea6007

### 第一部分 原文与翻译

**英文原标题：** Advances in machine learning-enhanced microfluidic cell sorting.

> **英文摘要：**
> Cell sorting, essential for diagnostics and early intervention, has evolved from conventional methods to sophisticated microfluidic approaches. These miniaturized systems leverage precise hydrodynamic control, facilitating major advances in tumor cell isolation, single-cell analysis, and biomarker detection. However, the vast imaging data generated by these microfluidic techniques necessitate advanced computational methods. Machine learning, particularly computer vision and deep learning, now offers transformative capabilities for automated feature extraction, pattern recognition, and real-time classification, enhancing sorting accuracy, accelerating diagnostics, and informing clinical decisions. This review synthesizes the convergence of microfluidics and machine intelligence, examining their synergistic roles in flow-field optimization, cellular classification, and error correction. While highlighting breakthroughs in diagnostic sensitivity and analytical throughput, we critically address challenges including model generalizability and hardware-software integration. Last, we provide an outlook on multimodal data fusion and the development of on-chip intelligent systems, proposing a roadmap for advancing precision medicine through embedded, adaptive biosensing platforms.

> **中文摘要：**
> 细胞分选作为诊断和早期干预的重要环节，已从传统方法发展为复杂的微流控技术。这些微型化系统利用精确的流体动力学控制，在肿瘤细胞分离、单细胞分析和生物标志物检测方面实现了重大进展。然而，这些微流控技术产生的大量成像数据亟需先进的计算方法。机器学习，尤其是计算机视觉和深度学习，如今为自动特征提取、模式识别和实时分类提供了变革性能力，从而提高分选精度，加快诊断过程，并为临床决策提供支持。本综述综合了微流控与机器智能的融合，探讨它们在流场优化、细胞分类和误差校正中的协同作用。在强调诊断灵敏度和分析通量突破的同时，本文也批判性地讨论了模型泛化性及软硬件集成等挑战。最后，我们展望了多模态数据融合与片上智能系统的发展，提出通过嵌入式、自适应生物传感平台促进精准医学的未来发展路线图。

### 第二部分 AI 大师评价

该综述文章系统总结了机器学习与微流控技术在细胞分选领域的融合进展，旨在提升诊断灵敏度与自动化水平。作者梳理了从特征提取、模式识别到实时分类的算法应用，并讨论其在流体控制和分类精度改进中的作用。文章的创新在于提出了结合计算智能与芯片系统的未来发展框架，为精准医学的嵌入式生物传感平台提供方向。然而，模型的普适性不足与软硬件耦合问题仍是实现临床转化的重要挑战。

---

## 44. 拓扑异构酶III-β可防止免疫失调和肿瘤发生

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41417894)
**期刊：** Science advances
**PMID：** 41417894
**DOI：** 10.1126/sciadv.ady7028

### 第一部分 原文与翻译

**英文原标题：** Topoisomerase III-beta protects from immune dysregulation and tumorigenesis.

> **英文摘要：**
> Topoisomerase III-beta (Top3b) reduces nucleic acid torsional stress and intertwining generated during RNA and DNA metabolism while protecting the genome from pathological R-loops, which otherwise result in DNA breakage and genome instability. By studying  knockout mice (-KO), we find that the loss of Top3b accelerates the development of spontaneous atypical lymphoid hyperplasia and lymphomas arising in spleens and lymph nodes, organs with prominent Top3b expression. Aging -KO mice also display splenomegaly and systemic immune alterations including neutrophilia and lymphopenia consistent with chronic inflammation. At the molecular level, Top3b deficiency causes genome-wide R-loop accumulation in splenocytes as measured by CUT&Tag sequencing. Increased R-loops are associated with genomic breaks and activation of immune signaling pathways including innate and adaptive immune cell signaling, IL-4 signaling, FAK signaling, and cGAS-STING. In addition, knocking-out  promotes the rapid development of syngeneic EL4 T cell lymphomas. In conclusion, our work implies that Top3b protects from lymphoma, tumorigenesis, and immune dysregulations.

> **中文摘要：**
> 拓扑异构酶III-β（Top3b）可在RNA和DNA代谢过程中减少核酸的扭转应力和缠结，并通过防止病理性R环的形成来保护基因组，因为R环的形成会导致DNA断裂和基因组不稳定。通过研究Top3b基因敲除小鼠（-KO），我们发现Top3b的缺失会加速脾脏和淋巴结中自发性非典型淋巴组织增生及淋巴瘤的发生，这些器官中Top3b的表达较为显著。老年Top3b-KO小鼠还表现出脾肿大以及包括中性粒细胞增多和淋巴细胞减少在内的系统性免疫改变，与慢性炎症一致。在分子水平上，通过CUT&Tag测序分析发现，Top3b缺陷会导致脾细胞中全基因组范围的R环积累。R环增多与基因组断裂及免疫信号通路的激活有关，包括固有和适应性免疫细胞信号传导、IL-4信号、FAK信号及cGAS-STING通路。此外，Top3b的缺失还促进了同系EL4 T细胞淋巴瘤的快速发展。总之，我们的研究表明，Top3b可防止淋巴瘤、肿瘤发生及免疫失调。

### 第二部分 AI 大师评价

本研究通过Top3b敲除小鼠模型揭示了拓扑异构酶III-β在维持基因组稳定性和防止免疫系统异常中的关键作用。作者综合使用分子测序与动物实验，发现Top3b缺失会诱发R环积累、DNA损伤以及免疫信号通路异常，最终促进淋巴瘤发生。该工作首次系统性地将R环代谢失衡与免疫失调及肿瘤发生联系起来，具有重要创新性。局限性在于尚需进一步阐明不同免疫细胞类型中Top3b的特异性作用机制。

---

## 45. VNUT介导的ATP释放通过P2X7R–JNK–FOXO3a–Eomes信号级联抑制T辅助1（T1）细胞分化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41417887)
**期刊：** Science advances
**PMID：** 41417887
**DOI：** 10.1126/sciadv.adz7600

### 第一部分 原文与翻译

**英文原标题：** VNUT-mediated ATP release suppresses T helper 1 (T1) cell differentiation via the P2X7R-JNK-FOXO3a-Eomes signaling cascade.

> **英文摘要：**
> Extracellular ATP (eATP), a well-recognized danger signal and immune activator, is implicated in the activation, differentiation, and function of T cells, directly or indirectly. Yet, how T cells release ATP themselves and its effects remain poorly investigated. Here, we found vesicular nucleotide transporter (VNUT), critical for vesicular ATP storage/release, is highly expressed in T1 cells and selectively restricts their differentiation and effector functions. Mechanistically, VNUT facilitates lysosomal ATP import and its extracellular release upon T cell receptor engagement. This eATP then activates the purinergic receptor P2X7R and downstream SRC kinase, triggering a signaling cascade involving heightened Ca influx and hyperphosphorylation of JNK and FOXO3a, which ultimately impairs Eomes-directed IFN-γ production in T1 cells. Genetic/pharmacological of VNUT inhibition significantly potentiates T1 effector functions against  infection and transplanted tumors. These findings identify VNUT as a critical checkpoint in limiting T1 immunity, coupling vesicular ATP transport to transcriptional control via the P2X7R-JNK-FOXO3a-Eomes axis, offering a target for treating infection and cancer.

> **中文摘要：**
> 细胞外ATP（eATP）是一种公认的危险信号和免疫激活因子，直接或间接参与T细胞的激活、分化和功能。然而，T细胞自身如何释放ATP及其效应仍缺乏深入研究。在本研究中，我们发现囊泡型核苷酸转运蛋白（VNUT），这一对囊泡内ATP储存和释放至关重要的分子，在T1细胞中高表达，并选择性地限制其分化和效应功能。在机制上，VNUT促进溶酶体ATP的摄取，并在T细胞受体激活时介导其释放至细胞外。随后，这些eATP激活嘌呤能受体P2X7R及其下游的SRC激酶，引发包括钙离子内流增强、JNK和FOXO3a过度磷酸化的信号级联反应，最终削弱Eomes驱动的T1细胞IFN-γ生成。通过基因或药理学方式抑制VNUT显著增强了T1细胞对感染和移植肿瘤的效应功能。这些发现将VNUT鉴定为限制T1免疫反应的关键检查点，将囊泡ATP转运与通过P2X7R–JNK–FOXO3a–Eomes轴的转录调控相联系，为感染和癌症治疗提供了新的靶点。

### 第二部分 AI 大师评价

该研究揭示了VNUT在调控T辅助1细胞分化中的关键作用，通过P2X7R–JNK–FOXO3a–Eomes信号通路连接囊泡ATP运输与转录调控。作者采用分子与细胞水平的机制研究，发现VNUT抑制T1细胞的效应功能，而其抑制可增强抗感染及抗肿瘤免疫。研究创新地提出ATP释放通路可作为免疫调控的新靶点，但其在其他T细胞亚群及体内长期免疫平衡中的影响仍需进一步验证。

---

## 46. 多细胞力协调构建用于跨细胞外基质无障碍转移的微通道网络

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41417886)
**期刊：** Science advances
**PMID：** 41417886
**DOI：** 10.1126/sciadv.adz4291

### 第一部分 原文与翻译

**英文原标题：** Multicellular force coordination constructs microchannel networks for barrier-free metastasis across extracellular matrix.

> **英文摘要：**
> The extracellular matrix (ECM) acts as a primary physical barrier to cancer metastasis. While individual cancer cells can remodel ECM to create microchannel-like paths of least resistance, this cell-centric view overlooks the coordinated dynamics of multicellular communication. Here, we reveal that cancer cells collaboratively reprogram ECM to construct interconnected microchannel networks functioning as "superhighways" for barrier-free metastasis. Combining live-cell imaging, atomic force microscopy, and optical tweezers, we decode that the indispensable step in microchannel network construction is organized cross-convergence of adjacent channels. The convergence is precisely directed by mechanical bridges composed of aligned collagen bundles between adjacent channels, which transmit orientation cues to induce multicellular force coordination. Integrating single-cell sequencing and off-lattice agent-based model, we identify mechanically responsive leader cells enriched for integrin-RhoA/YAP signaling and matrix metalloproteinase 14, which sense bridge cues and initiate cross-convergence. Collectively, our findings unveil a self-organized metastatic network and its mechanobiological mechanisms, offering a previously unidentified framework and potential therapeutic insights for cancer metastasis.

> **中文摘要：**
> 细胞外基质（ECM）是癌症转移的主要物理屏障。虽然单个癌细胞可以通过重塑ECM形成类似微通道的低阻力路径，但这种以细胞为中心的视角忽略了多细胞间协调通信的动态性。在此，我们揭示了癌细胞通过协同重编程ECM，构建互相连通的微通道网络，作为癌症无障碍转移的“高速通道”。结合活细胞成像、原子力显微镜和光镊技术，我们解码出微通道网络构建的关键步骤是相邻通道的有序交叉汇聚。该汇聚过程由位于相邻通道之间的胶原纤维束构成的机械桥精确引导，机械桥传递取向信号以诱导多细胞力的协调作用。通过整合单细胞测序与非晶格智能体模型，我们识别出对力学信号具有响应性的领头细胞，这些细胞富含整合素-RhoA/YAP信号通路及基质金属蛋白酶14，可感知机械桥信号并启动交叉汇聚。总体而言，我们的研究揭示了一个自组织的转移网络及其力学生物学机制，为理解癌症转移提供了全新的理论框架与潜在治疗思路。

### 第二部分 AI 大师评价

本研究聚焦于癌细胞在三维基质环境中的集体侵袭机制，提出了“多细胞力协调构建微通道网络”的新概念。研究通过多尺度成像与单细胞组学技术揭示了机械桥引导下的通道汇聚过程，并发现整合素-RhoA/YAP信号及MMP14在这一过程中发挥主导作用。该工作创新性地将力学信号与多细胞协同行为联系起来，为理解转移微环境的自组织机制提供了重要见解。然而，其模型仍主要基于体外系统，未来需在体内进一步验证其普适性。

---

## 47. 膜蛋白的精准调控：从物理技术到生物分子策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41417664)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41417664
**DOI：** 10.1002/advs.202510367

### 第一部分 原文与翻译

**英文原标题：** Precise Regulation of Membrane Proteins: From Physical Technology to Biomolecular Strategy.

> **英文摘要：**
> As essential functional components of the cell membrane, membrane proteins serve as one of the key mechanisms for sensing external stimuli and play crucial roles in diverse biological processes, including cell migration, proliferation, differentiation, and apoptosis. These processes are closely related to the maintenance of physiological homeostasis and the progression of various diseases. In recent years, with an in-depth understanding of membrane protein functions, developing membrane protein regulation strategies has emerged as a significant direction in both basic research and therapeutic applications. Precise modulation of membrane protein expression levels, conformational changes, and spatial distribution enables artificial regulation of cellular behavior, thereby opening promising avenues for treating diseases such as cancer, neurodegenerative disorders, and immune dysfunctions. This review comprehensively summarizes various physical technologies and biomolecule-driven approaches for membrane protein regulation, including applying light/temperature/magnetism/ultrasound-sensitive modules to achieve external physical control, as well as biomolecular tools, such as DNA, peptides, and proteins with specific receptor recognition properties that modulate membrane proteins via intermolecular interactions. Furthermore, the advantages and limitations of different membrane protein regulation techniques are discussed, aiming to provide new insights into cell function regulation and disease treatment.

> **中文摘要：**
> 作为细胞膜的重要功能组成部分，膜蛋白是感知外界刺激的关键机制之一，并在多种生物学过程中发挥着至关重要的作用，包括细胞迁移、增殖、分化和凋亡。这些过程与维持生理稳态及多种疾病的发展密切相关。近年来，随着对膜蛋白功能的深入理解，发展膜蛋白调控策略已成为基础研究和治疗应用中的重要方向。通过精确调节膜蛋白的表达水平、构象变化和空间分布，可以实现对细胞行为的人工调控，从而为治疗癌症、神经退行性疾病及免疫功能障碍等疾病开辟出有前景的新途径。本综述全面总结了膜蛋白调控的多种物理技术与生物分子驱动方法，包括利用光、温度、磁性、超声等敏感模块实现外源物理控制，以及利用具有特定受体识别特性的DNA、肽类和蛋白质等生物分子工具，通过分子间相互作用调节膜蛋白。此外，文章还讨论了不同膜蛋白调控技术的优势与局限性，旨在为细胞功能调控和疾病治疗提供新的启示。

### 第二部分 AI 大师评价

本文综述系统探讨了膜蛋白精确调控的多维策略，涵盖物理技术与生物分子手段两大方向。研究的核心目标在于通过调节膜蛋白的表达、构象及空间分布来实现细胞行为的人工控制，为疾病治疗提供新思路。文章的创新性在于综合分析多种外源物理刺激与生物分子识别机制的结合可能，为跨学科调控方法提供理论框架。然而，目前这些策略的可控性、特异性及在体应用仍需进一步验证。

---

## 48. MR-DELTAnet：一种纵向MRI-Transformer模型，用于预测局部晚期直肠癌病理完全缓解并通过单细胞RNA测序揭示免疫微环境。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41417633)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41417633
**DOI：** 10.1002/advs.202517721

### 第一部分 原文与翻译

**英文原标题：** MR-DELTAnet: A Longitudinal MRI-Transformer Model Predicting Pathological Complete Response and Revealing Immune Microenvironment via scRNA-seq in Locally Advanced Rectal Cancer.

> **英文摘要：**
> Accurate tumor response assessment to neoadjuvant chemoradiotherapy (NCRT) is crucial for personalized treatment strategies in locally advanced rectal cancer (LARC). However, reliable non-invasive assessment tool remains clinically lacking. To fill this unmet need, MR-DELTAnet, a longitudinal MRI-based Transformer framework that integrates Delta-Efficient Latent-Temporal Attention, is constructed to predict pathological complete response (pCR) to NCRT in locally advanced rectal cancer patients. In a multicenter retrospective cohort of 1,026 LARC patients between July 2012 and July 2023, MR-DELTAnet demonstrated robust discriminative performance across independent datasets, with the area under the curves (AUC) of 0.93 (95% CI 0.90-0.96), 0.88 (95% CI 0.82-0.94) and 0.90 (95% CI 0.79-1.00) and in training (n═633), internal validation (n═212) and external validation (n═181) sets, respectively. Risk-stratification by MR-DELTAnet prediction scores reveals significant survival differences: low-score patients exhibit prolonged disease-free and overall survival versus high-score patients (log-rank p<0.05). Applying the model to an independent single-cell RNA sequencing cohort (n═26) discloses biologically distinct immune microenvironments: high-score tumors are myeloid-rich and immunosuppressive, whereas low-score tumors harbor cytotoxic T-cell-dominant. Clinically, MR-DELTAnet provides an accurate, non-invasive tool for preoperative identification of pCR likelihood and biological phenotype, thereby potentially informing individualized treatment strategies for LARC management.

> **中文摘要：**
> 对局部晚期直肠癌（LARC）患者的新辅助放化疗（NCRT）反应进行准确评估，对于制定个体化治疗策略至关重要。然而，目前仍缺乏可靠的非侵入性评估工具。为满足这一未被满足的临床需求，研究者构建了MR-DELTAnet——一种基于纵向MRI的Transformer框架，融合了Delta高效潜时注意力机制，用于预测LARC患者对NCRT的病理完全缓解（pCR）。在2012年7月至2023年7月间纳入1,026例LARC患者的多中心回顾性队列中，MR-DELTAnet在独立数据集间展现出稳健的区分能力，其训练集（n＝633）、内部验证集（n＝212）及外部验证集（n＝181）的曲线下面积（AUC）分别为0.93（95% CI 0.90–0.96）、0.88（95% CI 0.82–0.94）和0.90（95% CI 0.79–1.00）。基于MR-DELTAnet预测分数的风险分层揭示了显著的生存差异：低分患者的无病生存期和总生存期明显长于高分患者（log-rank p<0.05）。将该模型应用于独立的单细胞RNA测序队列（n＝26）显示出生物学上截然不同的免疫微环境：高分肿瘤富含髓系细胞且呈免疫抑制状态，而低分肿瘤以细胞毒性T细胞为主。临床上，MR-DELTAnet提供了一种准确、非侵入性的术前工具，用于识别pCR可能性及生物学表型，从而有望为LARC的个体化管理提供参考。

### 第二部分 AI 大师评价

该研究旨在开发并验证一种利用纵向MRI序列的Transformer模型MR-DELTAnet，用于预测局部晚期直肠癌患者对新辅助放化疗的病理完全缓解。研究在大样本多中心队列中展示了优异的预测性能，并进一步通过单细胞转录组分析揭示了预测分层背后的免疫微环境差异。其创新性在于结合影像深度学习与分子特征，支持术前个体化决策。局限性可能在于模型需要多中心MRI规范化与外部前瞻性验证。

---

## 49. 纯母乳喂养通过AMPK依赖性的产热记忆调控棕色脂肪组织并促进后代长期代谢获益

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41417620)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41417620
**DOI：** 10.1002/advs.202508956

### 第一部分 原文与翻译

**英文原标题：** Exclusive Breastfeeding Drives AMPK-Dependent Thermogenic Memory in BAT and Promotes Long-Term Metabolic Benefits in Offspring.

> **英文摘要：**
> Exclusive breastfeeding reduces the risk of childhood obesity, potentially through metabolic programming of adipose tissue during lactation. However, the underlying mechanisms remain unclear. Using a mouse model, it is shown that mixed formula feeding disrupts brown adipose tissue (BAT) morphology, mitochondrial integrity, and thermogenic capacity, resulting in greater fat accumulation and glucose intolerance after weaning under a high-fat diet. By contrast, BAT from exclusively breastfed mice preserved enhanced thermogenic function for up to 12 weeks after transplantation into recipient mice. Transcriptomic analysis revealed that AMPK activation is sustained in BAT from exclusively breastfed mice but markedly diminished in mixed-fed counterparts. Pharmacological inhibition of AMPK abolished the long-term metabolic benefits conferred by exclusive breastfeeding. Mechanistically, breast milk-derived extracellular vesicles enriched in miR-125a-5p enhanced AMPK signaling by targeting HIF1AN. AMPK-induced α-ketoglutarate (αKG) production proved essential for BAT development and thermogenesis, and αKG supplementation rescued impaired BAT function in mixed-fed mice. In conclusion, exclusive breastfeeding imprints a thermogenic memory in BAT via the HIF1AN/AMPK/αKG signaling axis, thereby conferring long-term metabolic protection to offspring.

> **中文摘要：**
> 纯母乳喂养可降低儿童肥胖风险，这可能通过在哺乳期对脂肪组织进行代谢程序化来实现。然而，其潜在机制仍不清楚。通过使用小鼠模型，研究表明混合配方喂养会破坏棕色脂肪组织（BAT）的形态结构、线粒体完整性及产热能力，导致断奶后在高脂饮食条件下出现更多脂肪积聚和葡萄糖耐受不良。相比之下，纯母乳喂养小鼠的BAT在移植至受体小鼠后，仍可维持增强的产热功能长达12周。转录组分析显示，纯母乳喂养小鼠的BAT中AMPK活化持续存在，而混合喂养组则显著下降。药理性抑制AMPK会消除由纯母乳喂养带来的长期代谢益处。在机制层面，富含miR-125a-5p的乳汁来源细胞外囊泡通过靶向HIF1AN增强AMPK信号传导。AMPK诱导的α-酮戊二酸（αKG）生成对于BAT的发育和产热至关重要，而补充αKG可恢复混合喂养小鼠受损的BAT功能。综上，纯母乳喂养通过HIF1AN/AMPK/αKG信号轴在BAT中形成产热记忆，从而赋予后代长期的代谢保护。

### 第二部分 AI 大师评价

本研究揭示了纯母乳喂养通过AMPK途径在棕色脂肪组织中建立产热记忆，从而改善后代长期代谢健康。通过小鼠模型及转录组分析，研究团队明确了HIF1AN/AMPK/αKG信号轴在这一过程中起关键作用。乳汁来源的miR-125a-5p被证实可增强AMPK信号，揭示了母乳成分与代谢编程间的分子连接。该研究创新性地提出了“产热记忆”概念，但其动物模型结果仍需在人体研究中进一步验证。

---

## 50. 抑制TOPK通过eIF4F复合物介导的STAT1翻译促进胃癌抗肿瘤免疫。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41417572)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41417572
**DOI：** 10.1002/advs.202517380

### 第一部分 原文与翻译

**英文原标题：** TOPK Inhibition Promotes Anti-Tumor Immunity Via eIF4F Complex Mediated STAT1 Translation in Gastric Cancer.

> **英文摘要：**
> Immune checkpoint blockade-directed immunotherapy emerges as a revolutionary therapy in gastric cancer (GC). However, the proportion of patients who can benefit from it and its overall efficacy remain limited. Here the aim is to identify key dual-function targets that both inhibit proliferation and suppress immune evasion. Using whole genome-wide CRISPR-Cas9-based screening, the serine/threonine kinase T-lymphokine-activated killer cell-originated protein kinase (TOPK) is identified as a key regulator of PD-L1 in gastric cancer upon IFN-γ stimulation. Mechanical study is performed to explore the role of TOPK in promoting GC malignancy and immune evasion in vitro and vivo. Higher TOPK levels in tumor tissues are observed, correlated with clinical stages, efficacy and survival. Upon IFN-γ stimulation, TOPK phosphorylates eIF4F complex component eIF4A1 to increase its unwinding activity of STAT1 mRNA, enhancing STAT1 translation efficiency. This process leads to adaptive overexpression of PD-L1 and IDO1, resulting in immunometabolic suppression through PD-L1-mediated inhibition, IDO1-induced tryptophan depletion and kynurenine production. TOPK inhibitors reshape tumor immunometabolic microenvironment to trigger anti-tumor immunity in GC. The IFN-γ-TOPK-eIF4F-STAT1-PD-L1/IDO1 axis as a crucial regulator of the tumor immunometabolic microenvironment and provide novel insights into the combination of targeted therapy and immunotherapy for GC treatment.

> **中文摘要：**
> 免疫检查点阻断治疗在胃癌（GC）中崭露头角，成为一种革命性的治疗策略。然而，能够从该疗法中获益的患者比例及其总体疗效仍然有限。本研究旨在筛选既能抑制增殖又能阻断免疫逃逸的关键双功能靶点。通过全基因组范围的CRISPR-Cas9筛选，研究确定丝氨酸/苏氨酸激酶——T细胞来源的淋巴因子激活杀伤细胞蛋白激酶（TOPK）是在干扰素γ（IFN-γ）刺激下调控胃癌中PD-L1表达的关键调节因子。进一步的机制研究在体内外探讨TOPK在促进胃癌恶性进展与免疫逃逸中的作用。结果显示，肿瘤组织中TOPK水平升高，并与临床分期、治疗疗效及生存率显著相关。在IFN-γ刺激下，TOPK可磷酸化eIF4F复合物组分eIF4A1，增强其对STAT1 mRNA的解链活性，从而提升STAT1的翻译效率。该过程导致PD-L1与IDO1的适应性过度表达，并通过PD-L1介导的免疫抑制、IDO1诱导的色氨酸消耗及犬尿氨酸生成，引发免疫代谢抑制。TOPK抑制剂可重塑肿瘤免疫代谢微环境，从而激发胃癌的抗肿瘤免疫反应。IFN-γ–TOPK–eIF4F–STAT1–PD-L1/IDO1轴被确定为调控肿瘤免疫代谢微环境的关键途径，为胃癌靶向治疗与免疫治疗的联合策略提供了新的科学见解。

### 第二部分 AI 大师评价

本研究通过全基因组CRISPR筛选发现TOPK在胃癌免疫逃逸中发挥核心作用，并揭示其通过eIF4F复合物促进STAT1翻译的分子机制。研究创新性地构建了IFN-γ–TOPK–eIF4F–STAT1–PD-L1/IDO1信号轴模型，阐明其在免疫代谢调控中的作用。结果表明，抑制TOPK能够重塑肿瘤免疫代谢环境并增强抗肿瘤免疫。该研究为胃癌靶向治疗与免疫疗法结合提供了重要理论依据，但其临床可转化性仍需进一步验证。

---

## 51. DNMT2-m5C-ACLY 轴通过组蛋白乙酰化介导的 Notch 通路促进肝细胞癌的仑伐替尼耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41417568)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41417568
**DOI：** 10.1002/advs.202515931

### 第一部分 原文与翻译

**英文原标题：** DNMT2-m5C-ACLY Axis Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Through Histone Acetylation-Mediated Notch Pathway.

> **英文摘要：**
> Lenvatinib serves as a first-line therapy for advanced hepatocellular carcinoma (HCC), but its clinical efficacy is severely limited by acquired drug resistance. Consequently, the identification of therapeutic targets to reverse lenvatinib resistance may offer novel strategies to achieve enhanced and durable treatment responses. In this study, a global elevation in the levels of m5C modification is observed in lenvatinib-resistant cells compared with their parental counterparts. DNA methyltransferase 2(DNMT2), functioning as an RNA methyltransferase, is markedly upregulated in lenvatinib-resistant specimens and correlated with poor patient survival outcomes. Both in vitro and in vivo experiments indicated that DNMT2 downregulation effectively overcame lenvatinib resistance by reducing HCC cell proliferation and promoting apoptosis, thereby restoring drug sensitivity. Mechanistically, DNMT2 functioned together with Y-box binding protein 1 (YBX1) to stabilize downstream adenosine triphosphate citrate lyase (ACLY) mRNA through m5C modification. This process activated the Notch signaling pathway by increasing intracellular acetyl-CoA levels and promoting histone acetylation, driving the progression of lenvatinib resistance. Critically, pharmacological inhibition of ACLY combined with lenvatinib treatment enhanced the therapeutic efficacy against HCC and could reduce the tumor burden in multiple preclinical models. Collectively, the findings indicate the importance of the DNMT2-ACLY-NOTCH signaling axis in lenvatinib resistance and propose novel combinatorial therapies to improve HCC treatment outcomes.

> **中文摘要：**
> 仑伐替尼是晚期肝细胞癌（HCC）的一线治疗药物，但其临床疗效受到获得性耐药的严重限制。因此，识别可逆转仑伐替尼耐药的治疗靶点，可能为实现更强且持久的治疗反应提供新策略。在本研究中，与原代细胞相比，仑伐替尼耐药细胞中 m5C 修饰水平整体升高。作为 RNA 甲基转移酶的 DNA 甲基转移酶 2（DNMT2）在仑伐替尼耐药样本中显著上调，并与患者的不良生存结局相关。体外和体内实验均表明，通过下调 DNMT2，可有效克服仑伐替尼耐药，表现为抑制 HCC 细胞增殖并促进凋亡，从而恢复药物敏感性。在机制层面，DNMT2 与 Y-box 结合蛋白 1（YBX1）协同作用，通过 m5C 修饰稳定下游的腺苷三磷酸柠檬酸裂解酶（ACLY）mRNA。该过程通过增加细胞内乙酰辅酶 A 水平并促进组蛋白乙酰化，激活 Notch 信号通路，从而推动仑伐替尼耐药的进展。值得注意的是，在多种临床前模型中，ACLY 的药理学抑制与仑伐替尼联合治疗可增强抗肝癌的疗效并降低肿瘤负荷。总体而言，这些研究结果揭示了 DNMT2-ACLY-NOTCH 信号轴在仑伐替尼耐药中的重要作用，并提出了改进 HCC 治疗效果的新型联合治疗策略。

### 第二部分 AI 大师评价

该研究系统阐明了 DNMT2-ACLY-Notch 信号轴在肝细胞癌仑伐替尼耐药中的关键作用。研究者通过多层次的体内外实验揭示，DNMT2 通过 m5C 修饰稳定 ACLY mRNA，进一步促进组蛋白乙酰化和 Notch 通路激活，从而驱动耐药形成。联合使用 ACLY 抑制剂与仑伐替尼显著增强了抗肿瘤疗效，显示出潜在的临床转化价值。创新点在于将表观转录修饰与代谢及信号通路有机联系，但其临床可行性与药物安全性仍需进一步验证。

---

## 52. 半导体中的缺陷促生高性能器件

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41417557)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41417557
**DOI：** 10.1002/advs.202516270

### 第一部分 原文与翻译

**英文原标题：** Imperfection in Semiconductors Leading to High Performance Devices.

> **英文摘要：**
> Semiconductors form the basis of high-performance optoelectronic devices, enabling efficient light emission and detection. While crystalline perfection is generally sought to optimize device performance, specific lattice defects can endow materials with unexpected and useful functionalities. Here, we show that engineered defect states in gallium nitride (GaN) diodes markedly enhance their response to high-energy protons. Through a combination of device simulations and experimental measurements, we demonstrate that forward biasing the diode just below its turn-on voltage activates a defect-mediated photoconductive regime. This operating mode induces substantial carrier trapping and photoconductive gain while simultaneously suppressing the dark current-a behaviour in stark contrast to conventional photoconductors. The exploitation of this previously underexplored detection mechanism yields a three-orders-of-magnitude enhancement in sensitivity over standard photovoltaic operation, enabling reliable quantification of proton fluxes down to a few particles per second. This novel mode of operation is not limited to protons but also extends to X-rays and other high-energy particles, and may be generalized to a broader class of semiconductors exhibiting high levels of doping compensation. These findings open new avenues for very low-flux particle detection across diverse application spaces, including medical, astronomy, and industrial imaging.

> **中文摘要：**
> 半导体是高性能光电器件的基础，可实现高效的发光与探测。尽管通常追求晶体的完美以优化器件性能，但特定的晶格缺陷可以赋予材料出乎意料且有益的功能。在此，我们展示了经过工程化设计的氮化镓（GaN）二极管缺陷态，可显著增强其对高能质子的响应。通过将器件仿真与实验测量相结合，我们证明了当二极管的正向偏压略低于其开启电压时，会激活由缺陷介导的光电导模式。这种工作模式会引发显著的载流子俘获和光电导增益，同时抑制暗电流——这一行为与传统光电导体形成鲜明对比。利用这一此前鲜有研究的探测机制，灵敏度相比标准光伏工作模式提升了三个数量级，从而可可靠地量化每秒仅数个粒子的质子通量。这种新颖的工作模式不仅适用于质子，也可扩展至X射线及其他高能粒子，并可推广至表现出高掺杂补偿水平的更广泛类半导体体系。这些发现为超低通量粒子探测开辟了新的方向，涵盖医学、天文学及工业成像等多种应用领域。

### 第二部分 AI 大师评价

该研究探讨了半导体缺陷在高性能器件中的正向作用，通过在GaN二极管中设计特定缺陷态，实现了对高能粒子的高灵敏探测。作者利用仿真与实验证实，这种由缺陷介导的光电导机制在抑制暗电流的同时显著提升了灵敏度。其创新之处在于将传统视为不利因素的缺陷转化为性能增益点，展示了材料工程与器件物理结合的潜力。该方法有望推广至多种半导体体系，但其稳定性及缺陷可控性仍需进一步验证。

---

## 53. F13A1 介导的巨噬细胞活化通过 PKM2/HIF1A 通路促进代谢相关脂肪性肝炎（MASH）的进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41417477)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41417477
**DOI：** 10.1002/advs.202518128

### 第一部分 原文与翻译

**英文原标题：** F13A1-Mediated Macrophage Activation Promotes MASH Progression via the PKM2/HIF1A Pathway.

> **英文摘要：**
> Macrophages are central mediators of hepatic inflammation and fibrosis in metabolic-associated steatohepatitis (MASH), yet the mechanisms driving their activation remain unclear. Integration of four human single-nucleus transcriptomic datasets identified Coagulation Factor XIII-A (F13A1)-positive macrophages as the predominant subset in MASH livers, a finding validated in patient samples and murine models. Lipid-stressed hepatocytes induce F13A1 expression through a sphingosine-1-phosphate (S1P)-dependent mechanism. Silencing F13A1 suppressed the pro-inflammatory phenotype and alleviated hepatic injury in vivo. Mechanistically, F13A1 directly interacted with pyruvate kinase M2 (PKM2), promoting its dimerization, a process enhanced by intracellular calcium levels. Dimerized PKM2 translocated into the nucleus and upregulates interleukin-1 beta (IL1B) expression via the PKM2/HIF1A (Hypoxia-inducible factor 1-alpha) axis. In addition, F13A1 enhanced the Warburg effect in macrophages through PKM2-mediated metabolic reprogramming. Pharmacologic activation of PKM2 with DASA-58 abrogated F13A1-driven inflammation, and PEG-PLA micelle-mediated delivery of DASA-58 ameliorated hepatic inflammation in vivo. These findings establish F13A1 as a critical driver of macrophage-mediated inflammation in MASH and highlight the F13A1/PKM2/HIF1A pathway as a promising therapeutic target.

> **中文摘要：**
> 巨噬细胞是代谢相关脂肪性肝炎（MASH）中肝脏炎症和纤维化的核心介导者，但驱动其活化的机制仍不清楚。整合四个来源于人类的单核转录组学数据集后，研究发现凝血因子 XIII-A（F13A1）阳性的巨噬细胞是 MASH 肝脏中占优势的亚群，这一发现已在患者样本及小鼠模型中得到验证。脂质应激的肝细胞通过依赖于鞘氨醇-1-磷酸（S1P）的机制诱导 F13A1 的表达。沉默 F13A1 可抑制促炎表型并在体内缓解肝脏损伤。从机制上看，F13A1 直接与丙酮酸激酶 M2（PKM2）相互作用，促进其二聚化，而这一过程受胞内钙离子水平增强。二聚化的 PKM2 转位至细胞核内，并通过 PKM2/HIF1A（缺氧诱导因子 1-α）轴上调白介素-1β（IL1B）的表达。此外，F13A1 还通过 PKM2 介导的代谢重编程增强了巨噬细胞中的 Warburg 效应。药理性激活剂 DASA-58 可消除 F13A1 诱导的炎症反应，而通过 PEG-PLA 胶束递送 DASA-58 能够在体内改善肝脏炎症。这些发现确立了 F13A1 是 MASH 中巨噬细胞介导炎症的关键驱动因子，并强调了 F13A1/PKM2/HIF1A 通路作为潜在治疗靶点的前景。

### 第二部分 AI 大师评价

该研究系统揭示了 F13A1 在 MASH 发病机制中的关键作用，证明其通过与 PKM2 相互作用激活 HIF1A 信号轴，驱动巨噬细胞的炎症反应及代谢重编程。研究采用多组学整合、人样本验证及动物实验验证的方式，证据链完整且严谨。发现 DASA-58 可逆转 F13A1 引发的炎症，为 MASH 提供了潜在的代谢-免疫联合治疗靶点。其创新在于从代谢与免疫交叉角度揭示炎症调控新机制，但仍需进一步明确临床可转化性及安全性。

---

## 54. 探索血浆ctDNA与外周T细胞受体谱早期动力学以预测头颈癌PD-1抑制剂治疗结局

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41417470)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41417470
**DOI：** 10.1158/1078-0432.CCR-25-3541

### 第一部分 原文与翻译

**英文原标题：** Investigating Early Kinetics in Plasma ctDNA and Peripheral T Cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck Cancer.

> **英文摘要：**
> PURPOSE: Immune checkpoint blockade (ICB) therapies targeting the PD-1 axis have significantly improved survival in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Circulating tumor DNA (ctDNA) and peripheral T cell receptor (TCR) repertoires are emerging as promising biomarkers for predicting ICB response. Early characterization of ctDNA and TCR dynamics may enable timely treatment adjustments before clinical or radiological progression.
> 
> PATIENTS AND METHODS: The IO-KIN study (NCT04606940) is a single-center, prospective trial involving 15 patients with R/M HNSCC treated with nivolumab or pembrolizumab. Blood samples (n=104) were collected across seven timepoints from baseline to day 29. ctDNA was analyzed using a personalized assay (Signatera), and peripheral TCR repertoires were profiled using CapTCR-seq in eight patients.
> 
> RESULTS: A decline in ctDNA after day 8 was associated with radiological response, longer progression-free survival, and a trend toward improved overall survival. TCR repertoires transiently diversified between days 8-22, with longer diversification windows in patients showing sustained ctDNA decline. Using the GLIPHII algorithm, an EBV-specific TCR signature was identified and persisted in patients with clinical benefit. Additional TCR signatures, potentially recognizing tumor-associated antigens, emerged as early as day 3 and were linked to positive outcomes.
> 
> CONCLUSIONS: Simultaneous early monitoring of ctDNA and TCR dynamics reveals key determinants of ICB outcomes in R/M HNSCC. The transient nature of TCR diversification emphasizes the importance of precise sample timing to guide early therapeutic decisions and improve patient outcomes.

> **中文摘要：**
> 研究目的：针对PD-1轴的免疫检查点阻断（ICB）疗法显著改善了复发/转移性头颈鳞状细胞癌（R/M HNSCC）患者的生存。循环肿瘤DNA（ctDNA）和外周T细胞受体（TCR）谱系正成为预测ICB应答的潜在生物标志物。对ctDNA和TCR动力学的早期特征化可能在临床或影像学进展之前实现及时的治疗调整。
> 
> 患者与方法：IO-KIN研究（NCT04606940）是一项单中心、前瞻性试验，纳入15例接受nivolumab或pembrolizumab治疗的R/M HNSCC患者。共采集104份血样，覆盖从基线至第29天的7个时间点。使用个体化检测（Signatera）分析ctDNA，8例患者的外周TCR谱系则采用CapTCR-seq进行分析。
> 
> 结果：第8天后ctDNA下降与影像学应答、更长的无进展生存期及总体生存期改善趋势相关。TCR谱在第8至22天间出现瞬时多样化，在ctDNA持续下降的患者中多样化时间窗更长。通过GLIPHII算法鉴定出一种EB病毒特异性TCR特征，并在临床获益患者中持续存在。其他TCR特征（可能识别肿瘤相关抗原）最早在第3天出现，并与积极疗效相关。
> 
> 结论：对ctDNA与TCR动力学的同步早期监测揭示了R/M HNSCC中ICB疗效的关键决定因素。TCR多样化的瞬时性强调了精确采样时间的重要性，以指导早期治疗决策并改善患者预后。

### 第二部分 AI 大师评价

该研究旨在通过早期监测血浆ctDNA与外周TCR谱变化，预测PD-1抑制剂治疗头颈癌的疗效。研究采用前瞻性设计，结合个体化ctDNA检测与高通量TCR测序，揭示ctDNA下降及短暂TCR多样化与疗效相关。EBV特异性及肿瘤相关TCR信号的发现强化了免疫动态监测的潜在价值。其创新性在于整合双重免疫生物标志物实现早期疗效评估，而样本量较小与需多时间点采样是主要局限。

---

## 55. 携带 KRAS G12V 突变的非小细胞肺癌（NSCLC）患者的分子与临床特征

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41417462)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41417462
**DOI：** 10.1158/1078-0432.CCR-25-2581

### 第一部分 原文与翻译

**英文原标题：** Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS G12V mutations.

> **英文摘要：**
> PURPOSE: KRAS G12V is among the most frequent KRAS mutations in non-small cell lung cancer (NSCLC), yet its clinical and molecular features remain poorly understood.
> 
> EXPERIMENTAL DESIGN: In this retrospective study, we analyzed 636 patients with KRAS G12V-mutated NSCLC diagnosed between 2018 and 2023. Clinical, pathological, and molecular characteristics, including co-mutations, smoking history, PD-L1 expression, CD8+ T-cell infiltration, and treatment outcomes, were assessed.
> 
> RESULTS: The majority of patients (94.2%) were current or former smokers, with a median tobacco exposure of 40 pack-years. Co-mutations were frequent, most commonly in TP53 (40.2%), STK11 (30.2%), and KEAP1 (29.3%). Heavy smokers exhibited significantly higher PD-L1 expression and more frequent TP53, KEAP1, and NTRK1-3 mutations than light smokers. CD8+ T-cell infiltration showed a non-significant trend toward higher values in G12V compared to non-G12V KRAS subtypes. Among 151 patients with advanced disease, those treated with immune checkpoint blockade (ICB) alone or in combination with chemotherapy had significantly higher response rates and improved real-world progression-free (rwPFS) and overall survival (rwOS) compared to chemotherapy alone. In patients with PD-L1 TPS ≥50%, ICB-based treatment achieved a median rwOS of 30 months.
> 
> CONCLUSIONS: KRAS G12V-mutated NSCLC is characterized by a strong association with tobacco use, high co-mutation rates in clinically relevant genes, and a favorable response to PD-L1-based immunotherapy. The observed mutation landscape supports the potential for dual checkpoint blockade in a significant subset.

> **中文摘要：**
> 研究目的：KRAS G12V 是非小细胞肺癌（NSCLC）中最常见的 KRAS 突变类型之一，但其临床与分子特征尚不清楚。
> 
> 研究设计：在这项回顾性研究中，我们分析了 2018 至 2023 年间诊断为携带 KRAS G12V 突变的 NSCLC 患者共 636 例。评估了其临床、病理及分子特征，包括共突变、吸烟史、PD-L1 表达、CD8+ T 细胞浸润情况及治疗结局。
> 
> 研究结果：大多数患者（94.2%）为现吸烟者或既往吸烟者，中位烟草暴露量为 40 包年。共突变事件频繁，最常见于 TP53（40.2%）、STK11（30.2%）及 KEAP1（29.3%）基因。重度吸烟者的 PD-L1 表达显著升高，且 TP53、KEAP1 和 NTRK1–3 突变更为常见。与非 G12V 型 KRAS 亚型相比，G12V 型患者的 CD8+ T 细胞浸润呈现非显著性升高趋势。在 151 例晚期患者中，接受免疫检查点抑制剂（ICB）单药或联合化疗治疗者的应答率显著更高，且真实世界无进展生存期（rwPFS）和总生存期（rwOS）均优于单用化疗者。在 PD-L1 TPS ≥50% 的患者中，ICB 为基础的治疗可达中位 rwOS 30 个月。
> 
> 研究结论：KRAS G12V 突变型 NSCLC 与吸烟密切相关，具有高频临床相关基因共突变，并对以 PD-L1 为基础的免疫治疗具有良好反应。其突变图谱提示相当一部分患者可能从双重免疫检查点抑制获益。

### 第二部分 AI 大师评价

本研究系统分析了 KRAS G12V 突变型 NSCLC 的分子和临床特征，揭示其与吸烟密切关联，并伴随 TP53、STK11、KEAP1 等高频共突变。研究基于大样本回顾性队列，证实该亚型对 PD-L1 相关免疫治疗具有显著获益，尤其在高表达患者中生存期显著延长。其创新性在于提供了首个大规模、系统的 G12V 特征描述，并指出双重免疫检查点治疗的潜在价值。局限性在于回顾性设计及部分数据可能受真实世界偏倚影响。

---

## 56. 放射治疗后纤维板层型肝细胞癌患者的远隔效应反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/39709209)
**期刊：** Lancet (London, England)
**PMID：** 39709209
**DOI：** 10.1016/S0140-6736(24)02600-X

### 第一部分 原文与翻译

**英文原标题：** Abscopal response in a patient with fibrolamellar hepatocellular carcinoma following radiotherapy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

本病例报道描述了一名纤维板层型肝细胞癌患者在接受放射治疗后出现的远隔效应反应，提示局部放疗可能诱导全身抗肿瘤免疫反应。此类报道为理解放疗与免疫系统间的相互作用提供了罕见且有价值的临床证据。尽管研究局限于单病例，缺乏分子机制验证，但其发现具有重要的探索意义，为未来肝癌放疗及放免结合治疗策略的优化提供了启示。

---

## 57. 对英国临床实践中医师助理角色的关注

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/39709204)
**期刊：** Lancet (London, England)
**PMID：** 39709204
**DOI：** 10.1016/S0140-6736(24)02607-2

### 第一部分 原文与翻译

**英文原标题：** Concerns about the role of physician associates in UK clinical practice.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本刊文章聚焦于英国医疗体系中医师助理（Physician Associates, PA）的角色争议。尽管缺乏摘要，标题提示作者意在探讨该角色在临床实践中职责界定、职业边界及其对患者安全和医生工作结构的潜在影响。文章或基于政策背景和职业伦理层面提出问题，反映当前英国医疗工作分配与监管体系中存在的紧张与转型。其价值在于引发对医疗人力再定义和团队合作模式的深入讨论，但可能受限于缺乏实证数据支撑。

---

## 58. 全球、地区与国家层面对2030年全球营养目标的进展及至2050年的预测：全球疾病负担研究2021的系统分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/39667386)
**期刊：** Lancet (London, England)
**PMID：** 39667386
**DOI：** 10.1016/S0140-6736(24)01821-X

### 第一部分 原文与翻译

**英文原标题：** Global, regional, and national progress towards the 2030 global nutrition targets and forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021.

> **英文摘要：**
> BACKGROUND: The six global nutrition targets (GNTs) related to low birthweight, exclusive breastfeeding, child growth (ie, wasting, stunting, and overweight), and anaemia among females of reproductive age were chosen by the World Health Assembly in 2012 as key indicators of maternal and child health, but there has yet to be a comprehensive report on progress for the period 2012 to 2021. We aimed to evaluate levels, trends, and observed-to-expected progress in prevalence and attributable burden from 2012 to 2021, with prevalence projections to 2050, in 204 countries and territories.
> 
> METHODS: The prevalence and attributable burden of each target indicator were estimated by age group, sex, and year in 204 countries and territories from 2012 to 2021 in the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, the most comprehensive assessment of causes of death, disability, and risk factors to date. Country-specific relative performance to date was evaluated with a Bayesian meta-regression model that compares prevalence to expected values based on Socio-demographic Index (SDI), a composite indicator of societal development status. Target progress was forecasted from 2021 up to 2050 by modelling past trends with meta-regression using a combination of key quantities and then extrapolating future projections of those quantities.
> 
> FINDINGS: In 2021, a few countries had already met some of the GNTs: five for exclusive breastfeeding, four for stunting, 96 for child wasting, and three for child overweight, and none met the target for low birthweight or anaemia in females of reproductive age. Since 2012, the annualised rates of change (ARC) in the prevalence of child overweight increased in 201 countries and territories and ARC in the prevalence of anaemia in females of reproductive age decreased considerably in 26 countries. Between 2012 and 2021, SDI was strongly associated with indicator prevalence, apart from exclusive breastfeeding (|r-|=0·46-0·86). Many countries in sub-Saharan Africa had a decrease in the prevalence of multiple indicators that was more rapid than expected on the basis of SDI (the differences between observed and expected ARCs for child stunting and wasting were -0·5% and -1·3%, respectively). The ARC in the attributable burden of low birthweight, child stunting, and child wasting decreased faster than the ARC of the prevalence for each in most low-income and middle-income countries. In 2030, we project that 94 countries will meet one of the six targets, 21 countries will meet two targets, and 89 countries will not meet any targets. We project that seven countries will meet the target for exclusive breastfeeding, 28 for child stunting, and 101 for child wasting, and no countries will meet the targets for low birthweight, child overweight, and anaemia. In 2050, we project that seven additional countries will meet the target for exclusive breastfeeding, five for low birthweight, 96 for child stunting, nine for child wasting, and one for child overweight, and no countries are projected to meet the anaemia target.
> 
> INTERPRETATION: Based on current levels and past trends, few GNTs will be met by 2030. Major reductions in attributable burden for exclusive breastfeeding and anthropometric indicators should be recognised as huge scientific and policy successes, but the comparative lack of progress in reducing the prevalence of each, along with stagnant anaemia in women of reproductive age and widespread increases in child overweight, suggests a tenuous status quo. Continued investment in preventive and treatment efforts for acute childhood illness is crucial to prevent backsliding. Parallel development of effective treatments, along with commitment to multisectoral, long-term policies to address the determinants and causes of suboptimal nutrition, are sorely needed to gain ground.
> 
> FUNDING: Bill & Melinda Gates Foundation.

> **中文摘要：**
> 背景：世界卫生大会于2012年选定了六项全球营养目标（GNTs），涉及低出生体重、纯母乳喂养、儿童生长（即消瘦、发育迟缓和超重）以及育龄妇女贫血，作为母婴健康的关键指标。然而，目前尚无针对2012年至2021年期间进展的全面报告。我们的目标是评估2012年至2021年间在204个国家和地区的流行率水平、趋势、实际与预期进展情况及其可归因负担，并预测至2050年的流行率。
> 
> 方法：在全球疾病、伤害和危险因素研究2021（GBD 2021）中，按年龄组、性别和年份估算了204个国家和地区各目标指标的流行率及其可归因负担。该研究是迄今为止关于死亡、伤残和危险因素最全面的评估。通过基于社会人口指数（SDI，一种反映社会发展水平的综合指标）的贝叶斯元回归模型，评估了各国当前的相对表现。然后基于关键指标的组合，利用元回归对过去趋势建模并外推相关量的未来变化，以预测2021年至2050年的目标进展。
> 
> 结果：截至2021年，只有少数国家已达到部分营养目标：5个国家实现了纯母乳喂养目标，4个国家达到发育迟缓目标，96个国家达到儿童消瘦目标，3个国家达到儿童超重目标，而低出生体重和育龄妇女贫血目标均无人达成。自2012年以来，201个国家和地区儿童超重患病率的年变化率（ARC）上升，而26个国家育龄妇女贫血患病率的年变化率显著下降。在2012至2021年间，除纯母乳喂养外，SDI与各指标的流行率呈强相关（|r-|=0.46–0.86）。许多撒哈拉以南非洲国家多项指标的流行率下降速度超过了基于SDI的预期（儿童发育迟缓和消瘦的观测与预期ARC差值分别为-0.5%和-1.3%）。在大多数低收入和中等收入国家中，低出生体重、儿童发育迟缓和消瘦的可归因负担年变化率下降速度快于其对应的流行率变化率。我们预测，到2030年，将有94个国家实现6个目标中的一个，21个国家实现两个，而89个国家一个目标也未能达成。预计7个国家将达到纯母乳喂养目标，28个国家达到儿童发育迟缓目标，101个国家达到儿童消瘦目标，而无国家可达成低出生体重、儿童超重或贫血目标。展望2050年，预计额外7个国家可达成纯母乳喂养目标，5个国家达成低出生体重目标，96个国家达成儿童发育迟缓目标，9个国家达成儿童消瘦目标，1个国家达成儿童超重目标，而仍无国家能实现贫血目标。
> 
> 解释：基于当前水平和既往趋势，到2030年仅少数全球营养目标可能实现。纯母乳喂养和体格指标的可归因负担显著下降应被视为科学与政策的重大成功，但在减少其流行率上的进展有限，加上育龄妇女贫血停滞及儿童超重普遍上升，说明整体局势依然脆弱。持续投资于儿童急性疾病的预防与治疗至关重要，以防退步。同时，必须并行推动有效治疗手段的发展，并坚定实施多部门、长期政策，针对营养不良的决定因素与成因，方能取得实质进展。
> 
> 资助来源：比尔及梅琳达·盖茨基金会。

### 第二部分 AI 大师评价

本研究系统评估了2012至2021年间全球204个国家和地区在六项营养目标上的进展，并预测至2050年的趋势，系目前最全面的营养健康评估之一。研究采用GBD 2021数据及贝叶斯元回归建模，揭示多数指标与社会发展水平密切相关。结果显示，尽管部分国家在纯母乳喂养、儿童消瘦等方面取得成就，但总体达标率极低，且儿童超重和贫血问题持续存在。研究具有全球比较价值和前瞻性预测意义，但未来仍需加强数据质量及多部门政策落实，以推动全面营养改善。

---

## 59. 针对遗传性疾病患者的无毒治愈性方案。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/39642903)
**期刊：** Lancet (London, England)
**PMID：** 39642903
**DOI：** 10.1016/S0140-6736(24)02301-8

### 第一部分 原文与翻译

**英文原标题：** Non-toxic curative option for patients with genetic disorders.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 摘要不可用。

### 第二部分 AI 大师评价

本研究报告发表于《柳叶刀》，标题指向一种针对遗传性疾病患者的无毒治愈策略，显示出作者在探索安全性与疗效兼顾的新型基因治疗或分子干预途径。虽然当前缺乏正式摘要，仍可推测该研究旨在实现治疗与毒性控制的平衡，可能涉及创新的基因修复或细胞再编程技术。若结果得到验证，将对传统高风险基因治疗模式形成革新，但尚需明确临床证据以支持其可行性与长期安全性。

---

## 60. 未预处理Fanconi贫血-A患者的造血基因治疗：来自开放标签1/2期（FANCOLEN-1）及长期临床试验的结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/39642902)
**期刊：** Lancet (London, England)
**PMID：** 39642902
**DOI：** 10.1016/S0140-6736(24)01880-4

### 第一部分 原文与翻译

**英文原标题：** Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials.

> **英文摘要：**
> BACKGROUND: Allogeneic haematopoietic stem-cell transplantation is the standard treatment for bone marrow failure (BMF) in patients with Fanconi anaemia, but transplantation-associated complications such as an increased incidence of subsequent cancer are frequent. The aim of this study was to evaluate the safety and efficacy of the infusion of autologous gene-corrected haematopoietic stem cells as an alternative therapy for these patients.
> 
> METHODS: This was an open-label, investigator-initiated phase 1/2 clinical trial (FANCOLEN-1) and long-term follow-up trial (up to 7 years post-treatment) in Spain. Mobilised peripheral blood (PB) CD34 cells from nine patients with Fanconi anaemia-A in the early stages of BMF were transduced with a therapeutic FANCA-encoding lentiviral vector and re-infused without any cytotoxic conditioning treatment. The primary efficacy endpoint of FANCOLEN-1 was the engraftment of transduced cells, as defined by the detection of at least 0·1 therapeutic vector copies per nucleated cell of patient bone marrow (BM) or PB at the second year post-infusion, without this percentage having declined substantially over the previous year. The safety coprimary endpoint was adverse events during the 3 years after infusion. The completed open-label phase 1/2 and the ongoing long-term clinical trials are registered with ClinicalTrials.gov, NCT03157804; EudraCT, 2011-006100-12; and NCT04437771, respectively.
> 
> FINDINGS: There were eight evaluable treated patients with Fanconi anaemia-A. Patients were recruited between Jan 7, 2016 and April 3, 2019. The primary endpoint was met in five of the eight evaluable patients (62·50%). The median number of therapeutic vector copies per nucleated cell of patient BM and PB at the second year post-infusion was 0·18 (IQR 0·01-0·20) and 0·06 (0·01-0·19), respectively. No genotoxic events related to the gene therapy were observed. Most treatment-emergent adverse events (TEAEs) were non-serious and assessed as not related to therapeutic FANCA-encoding lentiviral vector. Nine serious adverse events (grade 3-4) were reported in six patients, one was considered related to medicinal product infusion, and all resolved without sequelae. Cytopenias and viral infections (common childhood illnesses) were the most frequently reported TEAEs.
> 
> INTERPRETATION: These results show for the first time that haematopoietic gene therapy without genotoxic conditioning enables sustained engraftment and reversal of BMF progression in patients with Fanconi anaemia.
> 
> FUNDING: European Commission, Instituto de Salud Carlos III, and Rocket Pharmaceuticals.

> **中文摘要：**
> 背景：异基因造血干细胞移植是Fanconi贫血患者骨髓衰竭（BMF）的标准治疗，但与移植相关的并发症（如继发癌症发生率升高）十分常见。本研究旨在评估自体基因矫正造血干细胞输注作为替代疗法的安全性与有效性。
> 
> 方法：这是一项在西班牙开展的开放标签、研究者发起的1/2期临床试验（FANCOLEN-1）及最长7年随访的长期研究。招募了9名处于BMF早期阶段的Fanconi贫血-A型患者，其动员外周血（PB）CD34+细胞经带有治疗性FANCA基因的慢病毒载体转导后，在未给予任何细胞毒性预处理的情况下回输。FANCOLEN-1试验的主要有效性终点为转导细胞的植入，即在输注后第二年时，患者骨髓（BM）或外周血中每个有核细胞的治疗性载体拷贝数至少达到0.1，并且该比例在前一年未明显下降。主要安全性终点为输注后3年内发生的不良事件。已完成的开放标签1/2期及正在进行的长期试验已在ClinicalTrials.gov注册：NCT03157804；EudraCT, 2011-006100-12；以及NCT04437771。
> 
> 结果：共有8名可评估的Fanconi贫血-A型患者接受治疗，招募时间为2016年1月7日至2019年4月3日。主要终点在8例中有5例（62.50%）达标。输注后第二年时，患者骨髓与外周血中每个有核细胞的治疗性载体拷贝数中位数分别为0.18（IQR 0.01–0.20）与0.06（0.01–0.19）。未观察到与基因治疗相关的基因毒性事件。大多数治疗出现的不良事件（TEAEs）为非严重且评估为与治疗性FANCA编码慢病毒载体无关。共有9例严重不良事件（3–4级）发生于6名患者，其中1例被认为与药物输注相关，所有病例均无后遗症地恢复。细胞减少与病毒感染（常见儿童感染）是最常见的TEAEs。
> 
> 结论：本研究首次证明，不经基因毒性预处理的造血基因治疗可在Fanconi贫血患者中实现持续性造血植入，并逆转骨髓衰竭的进展。
> 
> 资金来源：欧盟委员会、西班牙卡洛斯三世健康研究所及Rocket制药公司。

### 第二部分 AI 大师评价

该研究探索了Fanconi贫血-A型患者在无细胞毒性预处理条件下实施自体基因矫正造血干细胞治疗的可行性。研究设计为开放标签1/2期临床试验及长期随访，重点评估植入持续性与安全性。结果显示有约六成患者实现了持续植入且未观察到基因毒性事件，提示该疗法能够在较温和条件下逆转骨髓衰竭。该研究首次在人类中证实非预处理基因治疗的潜力，但样本量有限、随访时间尚需延长以验证长期获益与安全性。

---

速递结束，祝您工作愉快！